


RESEARCH ARTICLE

# Compartmentalized profiling of amniotic fluid cytokines in women with preterm labor

Gaurav Bhatti<sup>1,2</sup>, Roberto Romero<sup>1,3,4,5,6,7,\*</sup>, Gregory Edward Rice<sup>8\*</sup>, Wendy Fitzgerald<sup>9</sup>, Percy Pacora<sup>1,10</sup>, Nardhy Gomez-Lopez<sup>1,10,11</sup>, Mahendra Kavdia<sup>2</sup>, Adi L. Tarca<sup>1,10,12\*</sup>, Leonid Margolis<sup>9</sup>

**1** Perinatology Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Division of Intramural Research, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, Maryland, and Detroit Michigan, United States of America, **2** Department of Biomedical Engineering, Wayne State University College of Engineering, Detroit, Michigan, United States of America, **3** Department of Obstetrics and Gynecology, University of Michigan, Ann Arbor, Michigan, United States of America, **4** Department of Epidemiology and Biostatistics, Michigan State University, East Lansing, Michigan, United States of America, **5** Center for Molecular Medicine and Genetics, Wayne State University, Detroit, Michigan, United States of America, **6** Detroit Medical Center, Detroit, Michigan, United States of America, **7** Department of Obstetrics and Gynecology, Florida International University, Miami, Florida, United States of America, **8** Centre for Clinical Research, University of Queensland, Herston, Queensland, Australia, **9** Section on Intercellular Interactions, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, U.S. Department of Health and Human Services, Bethesda, Maryland, United States of America, **10** Department of Obstetrics and Gynecology, Wayne State University School of Medicine, Detroit, Michigan, United States of America, **11** Department of Biochemistry, Microbiology, and Immunology, Wayne State University School of Medicine, Detroit, Michigan, United States of America, **12** Department of Computer Science, Wayne State University College of Engineering, Detroit, Michigan, United States of America

\* [prbchiefstaff@med.wayne.edu](mailto:prbchiefstaff@med.wayne.edu) (RR); [g.rice@uq.edu.au](mailto:g.rice@uq.edu.au) (GER); [atarca@med.wayne.edu](mailto:atarca@med.wayne.edu) (ALT)



**OPEN ACCESS**

**Citation:** Bhatti G, Romero R, Rice GE, Fitzgerald W, Pacora P, Gomez-Lopez N, et al. (2020) Compartmentalized profiling of amniotic fluid cytokines in women with preterm labor. PLoS ONE 15(1): e0227881. <https://doi.org/10.1371/journal.pone.0227881>

**Editor:** Luca Giannella, Azienda Ospedaliero Universitaria Ospedali Riuniti di Ancona Umberto I G M Lancisi G Salesi, ITALY

**Received:** October 9, 2019

**Accepted:** December 31, 2019

**Published:** January 16, 2020

**Copyright:** This is an open access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the [Creative Commons CC0](https://creativecommons.org/licenses/by/4.0/) public domain dedication.

**Data Availability Statement:** The authors confirm that all data underlying the findings are fully available without restriction. All relevant data are within the Supporting Information files. [S3 Table](#) contains the proteomics data and relevant sample annotation.

**Funding:** This research was supported, in part, by the Perinatology Research Branch, Division of Obstetrics and Maternal-Fetal Medicine, Division of Intramural Research, Eunice Kennedy Shriver

## Abstract

### Objective

Amniotic fluid cytokines have been implicated in the mechanisms of preterm labor and birth. Cytokines can be packaged within or on the surface of extracellular vesicles. The main aim of this study was to test whether the protein abundance internal to and on the surface of extracellular vesicles changes in the presence of sterile intra-amniotic inflammation and proven intra-amniotic infection in women with preterm labor as compared to the women with preterm labor without either intra-amniotic inflammation or proven intra-amniotic infection.

### Study design

Women who had an episode of preterm labor and underwent an amniocentesis for the diagnosis of intra-amniotic infection or intra-amniotic inflammation were classified into three groups: 1) preterm labor without either intra-amniotic inflammation or proven intra-amniotic infection, 2) preterm labor with sterile intra-amniotic inflammation, and 3) preterm labor with intra-amniotic infection. The concentrations of 38 proteins were determined on the extracellular vesicle surface, within the vesicles, and in the soluble fraction of amniotic fluid.

National Institute of Child Health and Human Development, National Institutes of Health, U.S. Department of Health and Human Services (NICHD/NIH/DHHS); and, in part, with Federal funds from NICHD/NIH/DHHS under Contract No. HHSN275201300006C. Dr. Romero has contributed to this work as part of his official duties as an employee of the United States Federal Government. NG-L and ALT are supported by the Wayne State University Perinatal Research Initiative. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing interests:** The authors have declared that no competing interests exist.

## Results

1) Intra-amniotic inflammation, regardless of detected microbes, was associated with an increased abundance of amniotic fluid cytokines on the extracellular vesicle surface, within vesicles, and in the soluble fraction. These changes were most prominent in women with proven intra-amniotic infection. 2) Cytokine changes on the surface of extracellular vesicles were correlated with those determined in the soluble fraction; yet the magnitude of the increase was significantly different between these compartments. 3) The performance of prediction models of early preterm delivery based on measurements on the extracellular vesicle surface was equivalent to those based on the soluble fraction.

## Conclusions

Differential packaging of amniotic fluid cytokines in extracellular vesicles during preterm labor with sterile intra-amniotic inflammation or proven intra-amniotic infection is reported herein for the first time. The current study provides insights into the biology of the intra-amniotic fluid and may aid in the development of biomarkers for obstetrical disease.

## Introduction

Preterm birth (spontaneous and iatrogenic) is the leading cause of perinatal morbidity and mortality [1–6]. The keystone to improving health outcomes in women at risk of preterm birth is a thorough understanding of pathologic processes involved, identification of biomarkers, and implementation of therapeutic interventions. Of the risk factors identified for preterm birth, strong evidence supports the activation of intrauterine inflammatory pathways [7–17]. Consistent with these data, intra-amniotic inflammation due to microbial invasion of the amniotic cavity is an important cause of spontaneous preterm delivery [18–20], and the molecular mechanisms that may be responsible for parturition in this scenario have been extensively studied [18–35].

Proteins present in amniotic fluid, in particular cytokines, are key regulators of parturition, and labor-associated changes in their concentrations, with or without infection at both term and preterm, have been well characterized [36–62]. Until recently, regulatory activity of these proteins was considered to be mediated via soluble autocrine [63–66], paracrine [63, 65, 67], and endocrine [68–70] signaling pathways, by direct engagement with cell-surface receptors. However, it is now established that such mediators are also associated with extracellular vesicles (both ectosomes and exosomes) and are present both on the surface and within the lumen of vesicles [71–74]. Extracellular vesicle-associated proteins, therefore, represent an additional, and as yet uncharacterized, pathway that may contribute to the initiation of labor and delivery at both term and preterm.

Extracellular vesicles have been identified in amniotic fluid [75–87] and available data indicate that exosome concentrations may increase in labor, both at term and preterm [86]. Amnion epithelial and stem cells release extracellular vesicles *in vitro* [83, 84, 88–90] and, therefore, may contribute to the amount of extracellular vesicles in amniotic fluid *in vivo*. Additional sources of extracellular vesicles in amniotic fluid may include the fetal skin, urine, and lung.

Labor and delivery are associated with significant changes in the protein complement of amniotic fluid extracellular vesicles [86]. There is a paucity of data, however, about the role of

amniotic fluid extracellular vesicle-associated proteins in preterm labor and delivery and whether their presentation on extracellular vesicles changes in association with intra-uterine inflammation (with or without proven infection).

Herein, we tested the hypothesis that preterm labor with sterile intra-amniotic inflammation and preterm labor with intra-amniotic infection are associated with an increased expression of cytokines in extracellular vesicles present in amniotic fluid, and that such changes will differ between the different extracellular vesicle compartments (internal, surface) and the soluble fraction.

## Materials and methods

### Clinical cohort and study design

A retrospective, cross-sectional study was conducted that included women who had an episode of preterm labor and underwent an amniocentesis for the diagnosis of intra-amniotic infection or intra-amniotic inflammation. Amniotic fluid that was not used for clinical tests was retained for research purposes. These amniotic fluid samples were stored in the Bio-Repository of Wayne State University and the Detroit Medical Center. The Bio-Repository and associated patient data were curated using a commercially available sample inventory and resource management system (BSI Systems, Calverton, MD, USA) at the Perinatology Research Branch of the *Eunice Kennedy Shriver* National Institute of Child Health and Human Development (NICHD), National Institutes of Health, U.S. Department of Health and Human Services (Detroit, MI, USA). The inclusion criteria for this study required an episode of preterm labor, a singleton gestation, a transabdominal amniocentesis performed between 17 and 36 weeks of gestation with microbiologic studies, and a live-born fetus with available data regarding neonatal outcomes. Patients with placenta previa were excluded from the study or if their fetus had a chromosomal abnormality or structural anomaly.

The Institutional Review Boards of Wayne State University and/or National Institute of Child Health and Human Development (NICHD) / National Institutes of Health / U.S. Department of Health and Human Services (Detroit, MI, USA) approved the study. Specimens were collected under the protocols noted herein: Establishment of a Clinical Perinatal Database and a Bank of Biological Materials [WSU IRB# 082403MP2F (5R) and NICHD/NIH# OH98-CH-N001]; Biological Markers of Disease in the Prediction of Preterm Delivery, Preeclampsia and Intra-Uterine Growth Restriction: A Longitudinal Study (WSU IRB#110605MP2F and NICHD/NIH# OH97-CH-N067); Microarray Expression Profiling to Identify Stereotypic mRNA Profiles in Human Parturition (WSU IRB# 103108MP2F and NICHD/NIH # OH99-CH-N056); Cerebral Palsy: Clinical, Biochemical, Histological, and Biophysical Parameters in the Prediction of Cerebral Palsy in Patients with Preterm Labor and Premature Rupture of Membranes (NICHD/NIH# OH97-CH-N066); The Role of Feto-Maternal Inflammation as a Mechanism of Disease in the Great Obstetric Syndromes (WSU IRB# 075299M1E).

### Clinical definitions

Gestational age was determined by the date of the last menstrual period and confirmed by the first ultrasound examination or by ultrasound examination alone if the sonographic determination of gestational age was inconsistent with menstrual dating. **Term labor** was defined as the presence of regular uterine contractions with a frequency of at least 1 every 10 minutes and cervical changes occurring after 37 weeks of gestation [91]. **Preterm birth** was defined as delivery between 20 and 36<sup>6/7</sup> weeks of gestation. **Early preterm birth** was defined as delivery between 20 and 31<sup>6/7</sup> weeks of gestation. **Moderate to late preterm birth** was defined as

delivery between 32 and 36<sup>6/7</sup> weeks of gestation. **Term delivery** was defined as birth  $\geq 37$  weeks of gestation. **Intra-amniotic inflammation** was diagnosed when the concentration of interleukin 6 (IL-6) in the amniotic fluid was  $\geq 2.6$  ng/ml [92, 93]. **Microbial invasion of the amniotic cavity** was detected from a positive amniotic fluid culture and/or polymerase chain reaction/electrospray ionization-mass spectrometry (PCR-ESI/MS) result [18, 19, 94–101]. Based on the results of the amniotic fluid culture, PCR-ESI/MS, and amniotic fluid IL-6 concentration, patients were classified into the following groups:

1. Preterm labor without either intra-amniotic inflammation or detectable microbes in the amniotic cavity (control group,  $n = 88$ );
2. Preterm labor with intra-amniotic inflammation but without detectable microbes in the amniotic cavity (sterile intra-amniotic inflammation [SIAI] group,  $n = 19$ ); and
3. Preterm labor with detectable microbes in the amniotic cavity and intra-amniotic inflammation (proven intra-amniotic infection [IAI] group,  $n = 33$ ).

### Amniotic fluid samples

Amniotic fluid was retrieved either by transabdominal amniocentesis under antiseptic conditions using a 22-gauge needle monitored by ultrasound, or by amniocentesis during cesarean delivery under antiseptic conditions. Amniotic fluid samples were transported in capped, sterile syringes to the clinical laboratory and were cultured for aerobic and anaerobic bacteria as well as for genital mycoplasmas, as previously detailed [35]. At the time of collection, an amniotic fluid white blood cell count [102, 103], a glucose concentration [104] and a Gram stain [105] were performed. Concentrations of IL-6 [92] were determined either at the time of collection or from frozen plasma samples. Amniotic fluid samples used in this study were collected between 17.1 and 36.4 weeks of gestation and were stored at  $-70^{\circ}\text{C}$  until analysis.

### Preparation of extracellular vesicle fractions

Amniotic fluid samples were thawed at room temperature and treated with Exoquick-TC™ (System Biosciences, SBI, Palo Alto, CA, USA) to sediment the extracellular vesicles, according to the manufacturer's instructions. The resulting supernatants free of extracellular vesicles, and extracellular vesicle pellets re-suspended in the original starting volume, were collected for subsequent cytokine measurement.

### Cytokine measurement

The concentration of 38 cytokines (see S1 Table) was determined with an in-house multiplexed bead-based assay, using methods similar to those previously described [61]. All antibody pairs and protein standards were purchased from R&D Systems (Minneapolis MN, USA), except those for IFN- $\beta$  (Abcam, Cambridge, UK). Magnetic beads (Luminex Corporation, Austin, TX, USA) with distinct spectral signatures (regions) were coupled to analyte-specific capture antibodies, according to the manufacturer's recommendations, and stored at  $4^{\circ}\text{C}$ .

Samples and protein standards for the supernatant fluid and intact vesicles were prepared in assay buffer (1% bovine serum albumin in PBS), and lysed samples and standards were prepared in assay buffer with Triton™ X-100 at a final concentration of 0.5%. Samples and standards were combined with analyte-specific capture antibody coupled bead mixtures in 96-well flat bottom plates (Nunc, ThermoFisher Scientific, Waltham, MA, USA) and incubated at  $4^{\circ}\text{C}$  overnight. Plates were washed on a magnetic plate washer (405 TS, Biotek Winooski, VT, USA), followed by incubation with polyclonal biotinylated anti-analyte antibodies for 1 hour

at room temperature. Plates were washed and incubated for 30 minutes with 16  $\mu\text{g/ml}$  of streptavidin-phycoerythrin (ThermoFisher Scientific, Waltham, MA, USA) in PBS. Plates were washed and beads were re-suspended in PBS and read on a Luminex 200 analyzer (Luminex Corporation, Austin, TX, USA) with acquisition of 100 beads for each region and analyzed using Bioplex Manager software (Bio-Rad Laboratories, Hercules, CA, USA). Analyte concentrations (pg/ml) were determined using 5P regression algorithms and expressed as the mean pg/ml  $\pm$  S.E. Concentrations were corrected for dilution by ExoQuick-TC™ or Triton™ X-100. Extracellular vesicle luminal content was calculated as [analyte content of lysed vesicle] – [analyte content of intact vesicles].

## Statistical analyses

**Analysis of the demographic data.** Continuous variables were compared among multiple groups using the Welch's one-way analysis of variance (ANOVA) [106] or Kruskal-Wallis test, as appropriate. The Fisher's exact test was used to compare proportions in the analysis of contingency tables.

**Differences in protein concentration among groups by amniotic fluid compartment.** Protein concentrations were offset by adding 1 unit and then  $\log_2$  transformed to improve normality before analysis [107]. The transformed concentrations were then compared between pairs of the preterm labor groups, using the Wilcoxon rank sum test. Fold change in protein concentrations between groups was determined based on the median log transformed values in each group.

To test for differences in the magnitude of change among the preterm labor groups between different compartments (extracellular vesicle surface, extracellular vesicle internal, and amniotic fluid soluble fraction), a quantile regression model for repeated measures [108] was used for analysis—the transformed protein concentration was treated as the dependent variable, while the preterm labor group, the amniotic fluid compartment and gestational age at amniocentesis were treated as fixed effects. Differences in the effect of infection or inflammation on the cytokine abundance between compartments were tested by allowing for interaction terms in the regression models. The R package, *rqpd*, was used to estimate the model coefficients and their significance.

The Benjamini-Hochberg procedure [109] was employed to correct for multiple comparisons, and a q-value (corrected p-value) of less than 0.05 was considered a statistically significant result.

All analyses were performed using software packages within the R statistical environment [110].

**Prediction of preterm delivery.** An additional analysis was conducted to determine whether amniotic fluid compartmentalized protein abundance measured before 32 weeks of gestation is predictive of the time of delivery ( $<32$  vs  $\geq 32$  weeks of gestation). Random forest prediction models [111] were built for each of the three amniotic fluid compartments separately, as well as using data from all three amniotic fluid compartments at the same time. The *randomForest* in R was used to fit the models while allowing for 1,000 decision trees in each random forest model. Leave-one-out cross validation was used to estimate prediction performance indicators, including the area under the receiver operating characteristic (ROC) curves (AUC), sensitivity, and specificity.

## Results

### Clinical characteristics of the study population

Clinical characteristics of the patient population are summarized in [Table 1](#). No significant differences in maternal age, body mass index, gestational age at amniocentesis, gravidity, parity,

history of previous preterm delivery, and fetal gender were found among the 3 preterm labor groups. Gestational age at delivery, birthweight, 1- and 5-minute Apgar scores, frequency of clinical chorioamnionitis, amniotic fluid white blood cell count, and amniotic fluid glucose concentration varied significantly among the groups, consistent with clinical presentation. Among the patients with preterm labor with intra-amniotic infection, microorganisms were detected in the amniotic fluid through cultivation in 16 (48.5%) cases and through PCR/ESI-MS in 29 (88%) cases (S2 Table). The most common microorganisms detected included *Sneathia spp.* (n = 6), *Fusobacterium nucleatum* (n = 6), *Ureaplasma parvum* (n = 4), and *Ureaplasma urealyticum* (n = 4).

### Differences in protein concentration by amniotic fluid compartment among the groups

Protein concentrations by preterm labor group and amniotic fluid compartment are summarized as box plots in S1 Fig and data is available in S3 Table. Intra-amniotic inflammation, regardless of the detection of microorganisms, was associated with a pronounced expression of cytokines on the extracellular vesicle surface and in the soluble fraction of amniotic fluid (Fig 1). Pair-wise comparisons of protein concentration by amniotic fluid compartment are presented in Table 2 and illustrated in volcano plots (Fig 2). For some comparisons, even though the median protein concentrations were identical ( $\log_2$  fold change = 0) in the comparison groups, the Wilcoxon rank sum test returned a significant p-value (e.g. IL-1 $\alpha$ : preterm labor with intra-amniotic infection vs preterm labor without either intra-amniotic inflammation or proven intra-amniotic infection in the internal compartment of vesicles Table 2). In most cases, this was due to non-detection of protein (S4 Table) in majority of the samples resulting in median concentrations being zero for the two groups being compared. However, as was the case for IL-1 $\alpha$  (S1 Fig), among the samples in which the protein was detected, the concentrations were higher in one group compared to the other. Therefore, these comparisons were retained.

**Extracellular vesicle surface.** On the surface of extracellular vesicles, median concentrations of 37 proteins were significantly increased (q-value <0.05) in preterm labor with intra-amniotic infection compared to preterm labor without either intra-amniotic inflammation or proven intra-amniotic infection. The highest fold change (FC) was observed for MIP-3 $\alpha$  ( $\log_2$  FC = 10.5) followed by CXCL6 ( $\log_2$  FC = 8.6) and Calgranulin C ( $\log_2$  FC = 8.6). Median concentrations of 28 cytokines were significantly higher in preterm labor with sterile intra-amniotic inflammation compared to preterm labor without either intra-amniotic inflammation or proven intra-amniotic infection, with the highest fold changes being observed for Calgranulin C ( $\log_2$  FC = 7.7), MIP-3 $\alpha$  ( $\log_2$  FC = 6.8), and IL-6 ( $\log_2$  FC = 5.6). The comparison of intra-amniotic infection to sterile intra-amniotic inflammation groups identified 28 mediators with increased concentration [e.g., IL-33 ( $\log_2$  FC = 5.8), IFN- $\lambda$  ( $\log_2$  FC = 5.6), and MIP-1 $\alpha$  ( $\log_2$  FC = 4.5), among others].

**Extracellular vesicle internal compartment.** In the internal compartment of the extracellular vesicles, the median concentrations of 24 cytokines were significantly higher in preterm labor with intra-amniotic infection compared to preterm labor without either intra-amniotic inflammation or proven intra-amniotic infection. MIP-3 $\alpha$  ( $\log_2$  FC = 8.7), Calgranulin A ( $\log_2$  FC = 3.5), and IL-1 $\beta$  ( $\log_2$  FC = 2.3) showed the highest increase in concentration in the presence of intra-amniotic infection.

When comparing preterm labor with sterile intra-amniotic inflammation to preterm labor without either intra-amniotic inflammation or proven intra-amniotic infection, median concentrations of 5 cytokines [e.g. MIP-3 $\alpha$  ( $\log_2$  FC = 3.6), Calgranulin C ( $\log_2$  FC = 2.6), and IL-

**Table 1. Clinical characteristics of the study population.**

|   | PTL without either intra-amniotic inflammation or proven intra-amniotic infection (N = 88) | PTL with sterile intra-amniotic inflammation (N = 19) | PTL with intra-amniotic infection (N = 33) | P                   |
|---|--|---|--|---------------------|
| <b>Maternal</b>                                     |  |   |  |                     |
| Maternal Age (years)                                | 24.4(5.4)  | 24.3(4.3)   | 26.5(6.5)                                  | 0.223               |
| BMI*  | 25.7(7.2)  | 25.6(5.3)   | 29(8.2)                                    | 0.163               |
| Gestation Age at Amniocentesis                      | 26.7(5.3)  | 29.1(4.9)   | 25.7(3.8)                                  | 0.051               |
| African American Ethnicity                          | 77/88(87.5%)   | 15/19(78.9%)  | 26/33(78.8%)                               | 0.345               |
| Smoking   | 25/88(28.4%)   | 3/19(15.8%)   | 10/33(30.3%)                               | 0.51                |
| Alcohol*  | 6/86(7%)   | 1/19(5.3%)  | 1/33(3%)                                   | 0.868               |
| Drugs*  | 20/87(23%)   | 8/19(42.1%)   | 4/32(12.5%)                                | 0.057               |
| <b>Obstetric History</b>                            |  |   |  |                     |
| Primigravida  | 22/88(25%)   | 4/19(21.1%)   | 4/33(12.1%)                                | 0.307               |
| Term Deliveries                                     | 39/88(44.3%)   | 7/19(36.8%)   | 16/33(48.5%)                               | 0.705               |
| Preterm Deliveries                                  | 34/88(38.6%)   | 5/19(26.3%)   | 7/33(21.2%)                                | 0.171               |
| <b>Delivery</b>                                     |  |   |  |                     |
| Gestation Age at Delivery (weeks)*                  | 33.7(5.1)  | 29.5(4.8)   | 26.3(3.9)                                  | <0.001              |
| Induced Labor*                                      | 10/85(11.8%)   | 1/19(5.3%)  | 2/32(6.2%)                                 | 0.633               |
| C/S*  | 17/85(20%)   | 4/19(21.1%)   | 7/33(21.2%)                                | 1                   |
| Vaginal*  | 66/85(77.6%)   | 13/19(68.4%)  | 22/33(66.7%)                               | 0.388               |
| VBAC*   | 2/85(2.4%)   | 2/19(10.5%)   | 4/33(12.1%)                                | 0.052               |
| <b>Fetal</b>  |  |   |  |                     |
| Fetal Male Gender*                                  | 46/84(54.8%)   | 12/19(63.2%)  | 16/33(48.5%)                               | 0.598               |
| Birth Weight g*                                     | 2171.5(888.7)  | 1512(769.5)   | 1010.5(602.1)                              | <0.001              |
| Apgar 1 min < 5*                                    | 14/85(16.5%)   | 6/19(31.6%)   | 21/33(63.6%)                               | <0.001              |
| Apgar 5 min < 7*                                    | 14/85(16.5%)   | 7/19(36.8%)   | 20/33(60.6%)                               | <0.001              |
| Amniotic Fluid Glucose (mg/dl) < 14 mg/dl[104]*     | 2/83(2.4%)   | 2/17(11.8%)   | 16/30(53.3%)                               | <0.001              |
| Amniotic Fluid WBC (cells/mm3) ≥ 50 cells/mm3[102]* | 2/79(2.5%)   | 3/16(18.8%)   | 17/30(56.7%)                               | <0.001              |
| Amniotic Fluid RBC (cells/mm3)*                     | 11(3–48.8)   | 63(10–320)  | 23(6–120)                                  | 0.054 <sup>w</sup>  |
| Amniocentesis to Delivery (days interval)*          | 43.5(16.2–78.8)  | 2(1–3.5)  | 1(0–3)                                     | <0.001 <sup>w</sup> |
| <b>Complications</b>                                |  |   |  |                     |
| Preterm Premature Rupture of the Membranes          | 10/88(11.4%)   | 2/19(10.5%)   | 3/33(9.1%)                                 | 1                   |
| Small for Gestational Age Neonates                  | 11/88(12.5%)   | 1/19(5.3%)  | 0/33(0%)                                   | 0.071               |
| Preeclampsia  | 1/88(1.1%)   | 0/19(0%)  | 0/33(0%)                                   | 1                   |
| Clinical Chorioamnionitis                           | 3/88(3.4%)   | 2/19(10.5%)   | 8/33(24.2%)                                | 0.002               |


Continuous variable data are presented as the mean (standard deviation) when the differences among groups were assessed by ANOVA; or as median (interquartile range) when the Kruskal-Wallis test was performed. Count data are presented as number (%) and were compared using Fisher’s exact test.

\* Contain missing data

<sup>w</sup> Kruskal-Wallis one-way ANOVA

<https://doi.org/10.1371/journal.pone.0227881.t001>

1β (log2 FC = 0.9)] were significantly increased. Similarly, six cytokines [e.g., MIP-3α (log2 FC = 5.1), Calgranulin A (log2 FC = 4.5), and IL-4 (log2 FC = 1.8)] showed a significant increase in concentration in preterm labor with intra-amniotic infection compared to preterm labor with sterile intra-amniotic inflammation.



**Fig 1. Heatmap of protein concentrations on the extracellular vesicle surface, within the vesicle and in the soluble fraction of amniotic fluid.** The protein concentrations were offset by adding 1 unit,  $\log_2$  transformed, and then normalized (min-max normalization) separately for each amniotic fluid compartment.

<https://doi.org/10.1371/journal.pone.0227881.g001>

**Soluble fraction of amniotic fluid.** In the soluble fraction of amniotic fluid, median concentrations of 37 cytokines were significantly higher in preterm labor with intra-amniotic infection compared preterm labor without either intra-amniotic inflammation or proven intra-amniotic infection, with eotaxin-1, CXCL-6, and HMGB1 being the most increased ( $\log_2$  FC >10 for all). When comparing preterm labor with sterile intra-amniotic inflammation to preterm labor without either intra-amniotic inflammation or proven intra-amniotic infection, 20 cytokines showed significantly increased abundance, such as eotaxin-1 ( $\log_2$  FC = 10.6), CXCL6 ( $\log_2$  FC = 7), and Calgranulin C ( $\log_2$  FC = 5.1) (Table 2). Finally, 26 cytokines [e.g., IFN- $\gamma$  ( $\log_2$  FC = 4.9), CXCL6 ( $\log_2$  FC = 4), and IFN- $\lambda$  ( $\log_2$  FC = 3.3), among others] also showed a significant increase in preterm labor with intra-amniotic infection compared to preterm labor with sterile intra-amniotic inflammation.

### Compartment-dependent differences in protein abundance among three preterm labor groups

Quantile regression models were used to assess if the differences in protein abundance among preterm labor groups were significantly different among the three amniotic fluid compartments. For each pair-wise comparison among the study groups, the differences in  $\log_2$ -fold changes between the pairs of amniotic fluid compartments are provided in Table 3. Significant differences highlighted in Fig 3 (scatter plots of paired  $\log_2$  fold changes on the differences observed among the amniotic fluid compartments), are summarized below:

**The extracellular vesicle surface compartment versus the extracellular internal compartment.** The changes in protein abundance with intra-amniotic inflammation, regardless of the detection of microorganisms, were more pronounced on the extracellular vesicle surface



Table 2. Compartmentalized differential concentration analysis.


|               | Extracellular Vesicle Surface |                 |             | Extracellular Vesicle Internal |                 |             | Amniotic Fluid Soluble |                 |             |
|---------------|-------------------------------|-----------------|-------------|--------------------------------|-----------------|-------------|------------------------|-----------------|-------------|
|               | IAI vs Control                | SIAI vs Control | IAI vs SIAI | IAI vs Control                 | SIAI vs Control | IAI vs SIAI | IAI vs Control         | SIAI vs Control | IAI vs SIAI |
| IL-1α         | 3.4***                        | 0**             | 3.4*        | 0***                           | 0               | 0           | 5.3***                 | 2.1**           | 3.2*        |
| IL-1β         | 3.6***                        | 1.8***          | 1.9**       | 2.3***                         | 0.9***          | 1.4         | 5.6***                 | 2.7***          | 2.9***      |
| IL-2          | 1.4***                        | 0               | 1.4**       | 0***                           | 0*              | 0           | 4.3***                 | 1.8             | 2.5         |
| IL-4          | 3.3***                        | 1.6**           | 1.7**       | 1.8***                         | 0               | 1.8*        | 2.5***                 | 2.2***          | 0.4         |
| IL-6          | 6.7***                        | 3.4***          | 3.3**       | 1.6***                         | 0               | 1.6**       | 7.7***                 | 4.4***          | 3.2**       |
| IL-8          | 7.4***                        | 4***            | 3.4***      | 0**                            | 0               | 0           | 5.3***                 | 2.6***          | 2.7***      |
| IL-10         | 2.5***                        | 0.7***          | 1.8**       | 0***                           | 0               | 0           | 4.7***                 | 2.1***          | 2.6**       |
| IL-13         | 1.1***                        | 0**             | 1.1         |                                |                 |             | 3.8***                 | 2.9**           | 0.9         |
| IL-15         | 2.7***                        | 2.5**           | 0.2         | 1.1**                          | 0.2             | 0.8         | 0.4                    | -0.2            | 0.6         |
| IL-16         | 6.6***                        | 5.6***          | 1.1         | 0                              | 0               | 0           | 1.8***                 | 1.2             | 0.6*        |
| IL-18         | 0.6***                        | 0.7**           | -0.2        | 1**                            | 0.4             | 0.6         | 2***                   | 0.1             | 1.9**       |
| IL-33         | 5.8***                        | 0               | 5.8**       | 0***                           | 0               | 0           | 2.1***                 | 0               | 2.2**       |
| Calgranulin A | 5***                          | 2*              | 3**         | 3.5***                         | -1              | 4.5***      | 2.7***                 | 0.9*            | 1.8**       |
| Calgranulin C | 8.6***                        | 7.7***          | 1           | 0.8***                         | 2.6***          | -1.8        | 5.2***                 | 5.1***          | 0.1         |
| Eotaxin-1     | 7.6***                        | 5.3             | 2.3         | 0**                            | 0               | 0           | 11.1***                | 10.6*           | 0.5         |
| GMCSF         | 1.5***                        | 0.4*            | 1.2*        | 0                              | 0               |             | 4.9***                 | 4.7**           | 0.2         |
| Gro-α/CXCL-1  | 6.9***                        | 4.3***          | 2.5**       | 0                              | 0               | 0           | 3.7***                 | 1.7***          | 2**         |
| HMGB1         | 3.8***                        | 0               | 3.8         | 0*                             | 0               | 0           | 10.1***                | 0               | 10.1        |
| IFNγ          | 2.8***                        | 0.5*            | 2.3**       | 0***                           |                 | 0           | 6.6***                 | 1.7             | 4.9**       |
| IP-10         | 4.2***                        | 1.7*            | 2.6**       | 1.4                            | -1.1            | 2.6         | 1.5***                 | 0.6             | 1*          |
| ITAC/CXCL-11  | 8***                          | 5.4             | 2.6*        | 0***                           | 0               | 0           | 0.9**                  | -0.3            | 1.2*        |
| MCSF          | 1.1***                        | 0.5***          | 0.7*        | 0**                            | 0               | 0           | 1.9***                 | 0.6             | 1.3         |
| MCP-1         | 7.8***                        | 4.2***          | 3.6***      | 0                              | 0               | 0           | 5.1***                 | 1.9***          | 3.1***      |
| MIG           | 2.9***                        | 2**             | 0.9         | 0                              | 0               | 0           | 1.4***                 | 0.8             | 0.6         |
| MIP-1α        | 7.8***                        | 3.3***          | 4.5**       | 0***                           | 0***            | 0           | 6.9***                 | 3.7***          | 3.2**       |
| MIP-1β        | 6.5***                        | 4.4***          | 2.1**       | 0**                            | 0               | 0           | 6.6***                 | 4.5***          | 2.1**       |
| MIP-3α        | 10.5***                       | 6.8***          | 3.7**       | 8.7***                         | 3.6***          | 5.1**       | 5.2***                 | 2.2***          | 3**         |
| RANTES        | 5.3***                        | 3***            | 2.3**       | 0                              | 0               | 0           | 4.3***                 | 3.6***          | 0.8         |
| TGFβ          | 2.1***                        | 0               | 2.1***      | 0***                           | 0               | 0**         | 6.2***                 | 4.1***          | 2.1***      |
| TNFα          | 2.1***                        | 0**             | 2.1***      | 0.5***                         | 0               | 0.5**       | 4.7***                 | 1.8***          | 2.9***      |
| CRP           | 2**                           | 0.3             | 1.7**       | 0                              | 0               | 0           | 2.8***                 | 0.7             | 2.1*        |
| TRAIL         | 2.1***                        | 1.4*            | 0.7         | 0                              | 0               | 0           | 1.1***                 | 0.9             | 0.2         |
| CXCL6         | 8.6***                        | 4.3**           | 4.3***      | 0**                            | 0               | 0           | 11***                  | 7***            | 4***        |
| CXCL13        | 6.7***                        | 3.9***          | 2.7**       | 0*                             |                 | 0           | 2.7***                 | 0.7             | 2***        |
| MIF           | 1.6***                        | -0.1            | 1.7**       | 0.6                            | -1.6            | 2.2         | 0.9***                 | 0.2             | 0.7*        |
| IFNα          |                               |                 |             |                                |                 |             | 0**                    |                 | 0*          |
| IFNβ          | 2.1***                        | -0.9            | 3***        |                                |                 |             | 3.6***                 | 0.8             | 2.8***      |
| IFNλ          | 5.6***                        | 0*              | 5.6***      |                                |                 |             | 3***                   | -0.3            | 3.3**       |

Log<sub>2</sub> fold changes in protein abundance among the three preterm labor groups are presented for each compartment. Statistical significance was assessed by Wilcoxon rank sum test. IAI, preterm labor with intra-amniotic infection; SIAI, preterm labor with sterile intra-amniotic inflammation; Control, preterm labor without either intra-amniotic inflammation or proven intra-amniotic infection

Significance code for p-values:

- <0.001 “\*\*\*”,
- <0.01 “\*\*”,
- <0.05 “\*”

<https://doi.org/10.1371/journal.pone.0227881.t002>



**Fig 2. Volcano plot of  $-\log_{10}$  transformed p-values against  $\log_2$  transformed fold changes illustrating the changes in protein abundance with intra-amniotic infection and with sterile intra-amniotic inflammation.** Differentially abundant proteins ( $q$ -value  $< 0.05$ ) are highlighted in red. Changes in protein concentrations were most evident when comparing preterm labor with intra-amniotic infection to preterm labor without either intra-amniotic inflammation or proven intra-amniotic infection on the extracellular vesicle surface or in the soluble fraction of amniotic fluid. Control: preterm labor without either intra-amniotic inflammation or proven intra-amniotic infection.

<https://doi.org/10.1371/journal.pone.0227881.g002>

compared to the internal compartment (middle panel in Fig 3 and Table 3). For example, when comparing preterm labor with intra-amniotic infection vs preterm labor without either intra-amniotic inflammation or proven intra-amniotic infection, fold changes of 16 proteins were higher when assessed on the extracellular vesicle surface than internal to extracellular vesicles.

**The extracellular vesicle surface compartment versus the amniotic fluid soluble fraction.** A comparison of the data collected on the extracellular vesicle surface and in the soluble fraction of amniotic fluid revealed differences in the fold changes in protein abundance with intra-amniotic infection and with sterile intra-amniotic inflammation as follows: some cytokines showed significantly stronger associations on the extracellular vesicle surface and others in the soluble fraction of amniotic fluid (top panel in Fig 3 and Table 3). For example, when comparing preterm labor with intra-amniotic infection vs preterm labor without either intra-amniotic inflammation or proven intra-amniotic infection, fold changes of 15 proteins were significantly higher when assessed on the surface of extracellular vesicles compared to the

Table 3. Amniotic fluid between-compartment differences in the magnitude of changes in cytokine concentrations among preterm labor groups.

|                       | PTL with intra-amniotic infection vs PTL without either intra-amniotic inflammation or proven intra-amniotic infection |                     |                    | PTL with sterile intra-amniotic inflammation vs PTL without either intra-amniotic inflammation or proven intra-amniotic infection |                     |                    | PTL with intra-amniotic infection vs PTL with sterile intra-amniotic inflammation |                     |                    |
|-----------------------|--|---------------------|--------------------|---|---------------------|--------------------|---|---------------------|--------------------|
|                       | Surface vs Internal  | Soluble vs Internal | Soluble vs Surface | Surface vs Internal   | Soluble vs Internal | Soluble vs Surface | Surface vs Internal   | Soluble vs Internal | Soluble vs Surface |
| IL-1 $\alpha$         | 3.4**  | 5.3***              | 1.9*               | 0   | 2.1                 | 2.1                | 3.4   | 3.2                 | -0.2               |
| IL-1 $\beta$          | 1.3  | 3.3***              | 2***               | 0.9   | 1.8***              | 0.9**              | 0.5   | 1.5                 | 1                  |
| IL-2                  | 1.4***   | 4.3***              | 2.9***             | 0   | 1.8                 | 1.8                | 1.4***  | 2.5                 | 1.1                |
| IL-4                  | 1.5***   | 0.7                 | -0.8*              | 1.6**   | 2.2***              | 0.6                | -0.1  | -1.4*               | -1.3*              |
| IL-6                  | 5.1***   | 6.1***              | 1                  | 3.4***  | 4.4***              | 1                  | 1.7   | 1.6                 | -0.1               |
| IL-8                  | 7.4***   | 5.3***              | -2.1**             | 4***  | 2.6***              | -1.4               | 3.4   | 2.7                 | -0.7               |
| IL-10                 | 2.5***   | 4.7***              | 2.2***             | 0.7   | 2.1***              | 1.4**              | 1.8*  | 2.6***              | 0.8                |
| IL-13                 | 1.1**  | 3.8***              | 2.7***             | 0   | 2.9                 | 2.9                | 1.1*  | 0.9                 | -0.2               |
| IL-15                 | 1.6  | -0.7*               | -2.3***            | 2.3*  | -0.4                | -2.7***            | -0.6  | -0.2                | 0.4                |
| IL-16                 | 6.6***   | 1.8**               | -4.8***            | 5.6**   | 1.2                 | -4.4***            | 1.1   | 0.6                 | -0.5               |
| IL-18                 | -0.4   | 1**                 | 1.4**              | 0.3   | -0.3                | -0.6*              | -0.8  | 1.3*                | 2.1***             |
| IL-33                 | 5.8*   | 2.1                 | -3.7               | 0   | 0                   | 0                  | 5.8*  | 2.2                 | -3.6               |
| Calgranulin A         | 1.5  | -0.8                | -2.3               | 3**   | 1.9*                | -1.1               | -1.5  | -2.7                | -1.2               |
| Calgranulin C         | 7.8  | 4.4                 | -3.4**             | 5.1   | 2.5                 | -2.6**             | 2.8   | 1.9                 | -0.9               |
| Eotaxin-1             | 7.6*   | 11.1***             | 3.5***             | 5.3   | 10.6***             | 5.3*               | 2.3   | 0.5                 | -1.8               |
| GM-CSF                | 1.5***   | 4.9***              | 3.4***             | 0.4   | 4.7***              | 4.3***             | 1.2**   | 0.2                 | -1                 |
| Gro- $\alpha$ /CXCL-1 | 6.9***   | 3.7***              | -3.2**             | 4.3***  | 1.7***              | -2.6*              | 2.5**   | 2                   | -0.5               |
| HMGB1                 | 3.8  | 10.1                | 6.3                | 0   | 0                   | 0                  | 3.8   | 10.1                | 6.3                |
| IFN $\gamma$          | 2.8***   | 6.6***              | 3.8***             | 0.5   | 1.7                 | 1.2                | 2.3**   | 4.9                 | 2.6                |
| IP-10                 | 2.8  | 0.1                 | -2.7***            | 2.8   | 1.7                 | -1.1               | 0   | -1.6                | -1.6               |
| ITAC/CXCL-11          | 8  | 0.9                 | -7.1**             | 5.4*  | -0.3                | -5.7*              | 2.6   | 1.2                 | -1.4               |
| M-CSF                 | 1.1***   | 1.9***              | 0.8                | 0.5   | 0.6                 | 0.1                | 0.7   | 1.3                 | 0.6                |
| MCP-1                 | 7.8**  | 5.1                 | -2.7***            | 4.2***  | 1.9**               | -2.3*              | 3.6   | 3.1                 | -0.5               |
| MIG                   | 2.9  | 1.4                 | -1.5*              | 2   | 0.8                 | -1.2               | 0.9   | 0.6                 | -0.3               |
| MIP-1 $\alpha$        | 7.8***   | 6.9***              | -0.9               | 3.3**   | 3.7***              | 0.4                | 4.5*  | 3.2                 | -1.3               |
| MIP-1 $\beta$         | 6.5***   | 6.6***              | 0.1                | 4.4***  | 4.5***              | 0.1                | 2.1*  | 2.1                 | 0                  |
| MIP-3 $\alpha$        | 1.8  | -3.5***             | -5.3***            | 3.2   | -1.4*               | -4.6***            | -1.4  | -2.1                | -0.7               |
| RANTES                | 5.3***   | 4.3**               | -1**               | 3*  | 3.6**               | 0.6                | 2.3*  | 0.8                 | -1.5               |
| TGF $\beta$           | 2.1**  | 6.2***              | 4.1***             | 0   | 4.1***              | 4.1***             | 2.1*  | 2.1                 | 0                  |
| TNF $\alpha$          | 1.6***   | 4.2***              | 2.6***             | 0   | 1.8***              | 1.8***             | 1.6***  | 2.4**               | 0.8                |
| CRP                   | 2***   | 2.8***              | 0.8                | 0.3   | 0.7                 | 0.4                | 1.7***  | 2.1**               | 0.4                |
| TRAIL                 | 2.1***   | 1.1*                | -1**               | 1.4**   | 0.9                 | -0.5               | 0.7   | 0.2                 | -0.5               |
| CXCL6                 | 8.6***   | 11***               | 2.4***             | 4.3   | 7***                | 2.7                | 4.3*  | 4                   | -0.3               |
| CXCL13                | 6.7***   | 2.7***              | -4***              | 3.9***  | 0.7                 | -3.2***            | 2.7*  | 2*                  | -0.7               |
| MIF                   | 1  | 0.3                 | -0.7               | 1.5   | 1.8*                | 0.3                | -0.5  | -1.5                | -1                 |
| IFN $\beta$           | 2.1***   | 3.6***              | 1.5*               | -0.9  | 0.8                 | 1.7                | 3***  | 2.8***              | -0.2               |
| IFN $\lambda$         | 5.6***   | 3***                | -2.6***            | 0   | -0.3                | -0.3               | 5.6***  | 3.3                 | -2.3               |

Differences in the magnitude of changes in cytokine concentration with intra-amniotic infection and with sterile intra-amniotic inflammation were assessed between pairs of amniotic fluid compartments. Data represent differences in log<sub>2</sub> fold changes ( $\Delta$  log<sub>2</sub> FC) reported in Table 2. Statistical significance was assessed using quantile regression models. PTL: preterm labor.


Significance code for p-values:

<0.001 “\*\*\*”,

<0.01 “\*\*”,

< 0.05 “\*”

<https://doi.org/10.1371/journal.pone.0227881.t003>



**Fig 3. Scatter plot of fold changes in protein abundance with intra- amniotic infection and with sterile intra- amniotic inflammation between pairs of amniotic fluid compartments.** Proteins for which the changes were significantly different between compartments are highlighted in red. Data represents  $\log_2$  fold changes between groups. Control: preterm labor without either intra-amniotic inflammation or proven intra-amniotic infection.

<https://doi.org/10.1371/journal.pone.0227881.g003>

soluble amniotic fluid fraction; whereas fold changes of 13 proteins were higher in the soluble fraction of amniotic fluid compared to the extracellular vesicle surface.

**The extracellular vesicle internal compartment versus the amniotic fluid soluble fraction.** The changes in protein abundance with intra-amniotic inflammation, regardless of detected microorganisms, were generally lower when assessed within the extracellular vesicles than in the soluble fraction of amniotic fluid, with a few notable exceptions (bottom panel in Fig 3 and Table 3). For e.g., the fold changes in MIP-3 $\alpha$  with intra-amniotic infection and with sterile intra-amniotic inflammation were higher within vesicles compared to the soluble fraction of amniotic fluid (preterm labor with intra-amniotic infection vs preterm labor without either intra-amniotic inflammation or proven intra-amniotic infection:  $\Delta \log_2$  FC = 3.5; preterm labor with sterile intra-amniotic inflammation vs preterm labor without either intra-amniotic inflammation or proven intra-amniotic infection:  $\Delta \log_2$  FC = 1.4). Similarly, for IL-4, the change in protein abundance with intra-amniotic infection vs sterile intra-amniotic inflammation was higher within extracellular vesicles compared to that in the soluble fraction of amniotic fluid ( $\Delta \log_2$  FC = 1.4).

### Prediction of preterm delivery based on compartmentalized proteomic profiles of amniotic fluid

Of the 138 cases for which gestational age at delivery was available, 22 delivered at term ( $\geq 37$  weeks), 61 delivered early preterm ( $< 32$  weeks), and the 55 delivered late preterm (at or after 32 but before 37 weeks).

For the subset of cases where amniocentesis was performed before 32 weeks of gestation, the predictive value of the compartmentalized cytokine concentrations for early preterm delivery was evaluated by building univariate and multivariate prediction models. The performance of prediction models is summarized in Table 4 that gives the AUC statistic of univariate

Table 4. Prediction performance of early preterm delivery by single protein prediction models.

|                      | Extracellular vesicle Surface |         | Extracellular vesicle Internal |         | Amniotic fluid Soluble |         |
|----------------------|-------------------------------|---------|--------------------------------|---------|------------------------|---------|
|                      | AUC                           | q-value | AUC                            | q-value | AUC                    | q-value |
| <b>IL-1α</b>         | 0.71(0.64–0.79)               | <0.001  | 0.6(0.54–0.67)                 | 0.050   | 0.68(0.58–0.78)        | 0.003   |
| <b>IL-1β</b>         | 0.77(0.68–0.86)               | <0.001  | 0.68(0.58–0.78)                | 0.012   | 0.77(0.68–0.86)        | <0.001  |
| <b>IL-2</b>          | 0.66(0.58–0.75)               | 0.002   | 0.57(0.5–0.64)                 | 0.127   | 0.65(0.56–0.74)        | 0.006   |
| <b>IL-4</b>          | 0.73(0.64–0.83)               | <0.001  | 0.61(0.51–0.71)                | 0.114   | 0.73(0.63–0.83)        | <0.001  |
| <b>IL-6</b>          | 0.87(0.8–0.94)                | <0.001  | 0.59(0.5–0.69)                 | 0.127   | 0.84(0.76–0.92)        | <0.001  |
| <b>IL-8</b>          | 0.88(0.81–0.94)               | <0.001  | 0.57(0.5–0.63)                 | 0.127   | 0.85(0.77–0.93)        | <0.001  |
| <b>IL-10</b>         | 0.76(0.67–0.85)               | <0.001  | 0.53(0.45–0.61)                | 0.546   | 0.81(0.73–0.9)         | <0.001  |
| <b>IL-13</b>         | 0.67(0.6–0.73)                | <0.001  | 0.51(0.49–0.52)                | 0.515   | 0.71(0.62–0.79)        | <0.001  |
| <b>IL-15</b>         | 0.62(0.52–0.72)               | 0.032   | 0.54(0.43–0.65)                | 0.546   | 0.51(0.4–0.62)         | 0.879   |
| <b>IL-16</b>         | 0.69(0.59–0.79)               | 0.001   | 0.56(0.48–0.65)                | 0.210   | 0.67(0.57–0.78)        | 0.004   |
| <b>IL-18</b>         | 0.6(0.49–0.71)                | 0.098   | 0.62(0.51–0.72)                | 0.114   | 0.68(0.58–0.78)        | 0.003   |
| <b>IL-33</b>         | 0.65(0.57–0.73)               | 0.002   | 0.61(0.54–0.68)                | 0.050   | 0.62(0.52–0.73)        | 0.033   |
| <b>Calgranulin A</b> | 0.73(0.64–0.82)               | <0.001  | 0.61(0.5–0.71)                 | 0.127   | 0.74(0.65–0.84)        | <0.001  |
| <b>Calgranulin C</b> | 0.79(0.71–0.86)               | <0.001  | 0.64(0.57–0.71)                | 0.012   | 0.85(0.78–0.92)        | <0.001  |
| <b>Eotaxin-1</b>     | 0.67(0.58–0.76)               | 0.002   | 0.57(0.5–0.64)                 | 0.127   | 0.63(0.52–0.73)        | 0.025   |
| <b>GMCSF</b>         | 0.63(0.55–0.71)               | 0.007   | 0.47(0.43–0.52)                | 0.240   | 0.67(0.57–0.77)        | 0.004   |
| <b>Gro-α/CXCL1</b>   | 0.73(0.64–0.82)               | <0.001  | 0.57(0.5–0.64)                 | 0.146   | 0.77(0.67–0.86)        | <0.001  |
| <b>HMGB1</b>         | 0.6(0.52–0.68)                | 0.026   | 0.53(0.48–0.57)                | 0.453   | 0.61(0.52–0.7)         | 0.036   |
| <b>IFNγ</b>          | 0.69(0.61–0.78)               | <0.001  | 0.59(0.53–0.64)                | 0.050   | 0.69(0.59–0.78)        | 0.001   |
| <b>IP10</b>          | 0.7(0.6–0.8)                  | 0.001   | 0.57(0.46–0.68)                | 0.339   | 0.68(0.57–0.78)        | 0.004   |
| <b>ITAC/CXCL11</b>   | 0.64(0.54–0.74)               | 0.014   | 0.58(0.51–0.66)                | 0.114   | 0.56(0.45–0.67)        | 0.303   |
| <b>MCSF</b>          | 0.76(0.67–0.84)               | <0.001  | 0.56(0.49–0.63)                | 0.172   | 0.66(0.55–0.76)        | 0.009   |
| <b>MCP1</b>          | 0.83(0.75–0.91)               | <0.001  | 0.48(0.38–0.58)                | 0.711   | 0.85(0.78–0.93)        | <0.001  |
| <b>MIG</b>           | 0.68(0.58–0.78)               | 0.002   | 0.53(0.43–0.63)                | 0.636   | 0.59(0.48–0.7)         | 0.130   |
| <b>MIP-1α</b>        | 0.82(0.75–0.89)               | <0.001  | 0.58(0.51–0.65)                | 0.114   | 0.87(0.8–0.94)         | <0.001  |
| <b>MIP-1β</b>        | 0.84(0.77–0.92)               | <0.001  | 0.57(0.5–0.63)                 | 0.127   | 0.83(0.75–0.92)        | <0.001  |
| <b>MIP-3α</b>        | 0.78(0.7–0.87)                | <0.001  | 0.75(0.67–0.83)                | <0.001  | 0.87(0.8–0.94)         | <0.001  |
| <b>RANTES</b>        | 0.78(0.7–0.87)                | <0.001  | 0.61(0.51–0.7)                 | 0.114   | 0.81(0.73–0.9)         | <0.001  |
| <b>TGFβ</b>          | 0.71(0.63–0.79)               | <0.001  | 0.58(0.52–0.65)                | 0.114   | 0.76(0.67–0.84)        | <0.001  |
| <b>TNFα</b>          | 0.76(0.69–0.82)               | <0.001  | 0.67(0.61–0.74)                | 0.001   | 0.81(0.73–0.89)        | <0.001  |
| <b>CRP</b>           | 0.65(0.55–0.76)               | 0.010   | 0.51(0.42–0.59)                | 0.896   | 0.64(0.53–0.75)        | 0.020   |
| <b>TRAIL</b>         | 0.59(0.48–0.7)                | 0.115   | 0.52(0.46–0.58)                | 0.595   | 0.57(0.45–0.68)        | 0.265   |
| <b>CXCL6</b>         | 0.77(0.69–0.85)               | <0.001  | 0.57(0.51–0.63)                | 0.114   | 0.83(0.76–0.91)        | <0.001  |
| <b>CXCL13</b>        | 0.79(0.71–0.87)               | <0.001  | 0.54(0.49–0.58)                | 0.202   | 0.74(0.64–0.83)        | <0.001  |
| <b>MIF</b>           | 0.59(0.48–0.7)                | 0.122   | 0.54(0.42–0.65)                | 0.595   | 0.66(0.56–0.77)        | 0.006   |
| <b>IFNα</b>          |                               |         |                                |         | 0.57(0.52–0.61)        | 0.018   |
| <b>IFNβ</b>          | 0.61(0.5–0.71)                | 0.074   |                                |         | 0.76(0.67–0.85)        | <0.001  |
| <b>IFNλ</b>          | 0.74(0.67–0.81)               | <0.001  |                                |         | 0.7(0.6–0.8)           | 0.001   |

Area Under the Receiver Operating Characteristic Curve (AUC) for univariate prediction models using data collected from each amniotic fluid compartment separately, are presented along with their 95% confidence intervals and q-values (adjusted p-values from Wilcoxon rank sum test for differences between early preterm delivery and moderate to late preterm or term delivery).

<https://doi.org/10.1371/journal.pone.0227881.t004>

Table 5. Prediction performance of early preterm delivery by multivariate protein prediction models.

| Model                          | Sensitivity         | Specificity         | Positive likelihood ratio | Negative likelihood ratio | AUC                 |
|--------------------------------|---------------------|---------------------|---------------------------|---------------------------|---------------------|
| Amniotic fluid Soluble         | 0.74<br>(0.61–0.84) | 0.93<br>(0.81–0.99) | 10.57<br>(3.51–31.82)     | 0.28<br>(0.18–0.43)       | 0.86<br>(0.79–0.93) |
| Extracellular vesicle Surface  | 0.7<br>(0.57–0.81)  | 0.91<br>(0.78–0.97) | 7.58<br>(2.94–19.54)      | 0.33<br>(0.22–0.49)       | 0.85<br>(0.78–0.93) |
| Extracellular vesicle Internal | 0.67<br>(0.54–0.79) | 0.72<br>(0.56–0.85) | 2.41<br>(1.44–4.02)       | 0.45<br>(0.3–0.68)        | 0.73<br>(0.64–0.83) |
| Combined                       | 0.74<br>(0.61–0.84) | 0.93<br>(0.81–0.99) | 10.57<br>(3.51–31.82)     | 0.28<br>(0.18–0.43)       | 0.86<br>(0.78–0.93) |

Prediction performance metrics for early preterm delivery (<32 weeks of gestation) is given for multivariate predictive models, using as predictors the compartmentalized protein concentration profiles. Statistics are presented along with their 95% confidence intervals. The prevalence of early preterm delivery (<32 weeks of gestation) in the United States was 1.59% in 2017 [112].

<https://doi.org/10.1371/journal.pone.0227881.t005>

models by amniotic fluid compartment, in Table 5 that provides the performance metrics (sensitivity, and specificity) of multivariate models, and Fig 4 that displays the Receiver Operating Characteristic curves of multivariate models by amniotic fluid compartment.


For 33 cytokines, the AUC estimates obtained from univariate models based on their extracellular vesicle surface concentrations were significantly higher than 0.5 [e.g. IL-8 0.88(0.81–0.94), IL-6 0.87(0.8–0.94), MIP-1 $\beta$  0.84(0.77–0.92)]. Moreover, the AUC statistic for 16 of these cytokines (e.g. IL-15, MCSF, MIG, and ITAC/CXCL11, among others) was higher based on data collected on the extracellular vesicle surface than the data collected in the soluble fraction of amniotic fluid, yet the difference failed to reach statistical significance. The AUC estimates based on their extracellular vesicle internal concentrations were generally lower than the extracellular vesicle surface or amniotic fluid soluble counterparts (Table 4).

The performance indicators of multivariate models based on cytokine measurements in the extracellular vesicle internal, extracellular vesicle surface, and amniotic fluid soluble compartments were overall similar [EV Internal AUC = 0.73 (0.64–0.83), EV Surface AUC = 0.85 (0.78–0.93), Soluble fraction AUC = 0.86 (0.79–0.93)]. The top five ranked cytokines, based on their importance in prediction, were found in these compartments: EV surface: IL-6, IL-8, MCP-1, MIP-1 $\beta$ , and MIP-1 $\alpha$ ; EV internal: Calgranulin C, IP-10, MIP-3 $\alpha$ , IL-1 $\beta$ , and MIF; and amniotic fluid soluble: MIP-1 $\alpha$ , MIP-1 $\beta$ , MIP-3 $\alpha$ , IL-6, and IL-8. There was no significant improvement in the cross-validated point estimate of AUC of a multivariate early preterm delivery prediction model when information from all three compartments was used [AUC = 0.86 (0.78–0.93)] as compared to individual compartments.

## Discussion

Pathologic insults to the fetoplacental unit are often clinically expressed as complications of pregnancy, such as preterm labor with intact membranes and preterm prelabor rupture of the membranes [113–115]. A contemporary paradigm of the initiation of labor and delivery, both at term and preterm, involves the activation of intrauterine inflammatory signaling pathways and a shift to a more pro-inflammatory intra-amniotic environment [35, 60, 61, 96–101, 103, 116–128].

In addition to these canonical signaling pathways, recent studies identified the release of extracellular vesicles as a significant pathway for intercellular communication [129, 130]. The release of extracellular vesicles is an evolutionarily conserved effector and intercellular-signaling pathway and has been described in archeocian [131], prokaryotic [132], and eukaryotic [133–137] cells. Extracellular vesicles, including exosomes (nanovesicles of late endoplasmic



**Fig 4. Receiver operating characteristic (ROC) curves of multivariate predictive models for early preterm delivery (<32 weeks of gestation).** The Area Under the Receiver Operating Characteristic Curve (AUC) and 95% confidence interval are reported.

<https://doi.org/10.1371/journal.pone.0227881.g004>

reticulum origin and released via the fusion of multivesicular bodies with the plasma membrane) and ectosomes (nanovesicles formed by the direct budding of the plasma membrane) [130, 138], are derived from distinct biogenic pathways. They may share common functional activities but are profoundly different in their origin, biogenesis, distribution, release mechanisms, and response to stimuli [139]. In contrast to well-characterized endocrine signaling pathways, extracellular vesicle-dependent communication allows the exchange of proteins [140], RNA [140, 141], and DNA [142], with conformational fidelity.

Extracellular vesicles regulate inflammatory and immune processes [89, 143–158] and are present in amniotic fluid [75, 76, 81, 159, 160]. Amnion-derived extracellular vesicles are biologically active as mediators of proliferation, apoptosis, immune responses, angiogenesis, and inflammation [78, 79, 81] and may participate in labor-associated paracrine signaling [86, 90, 161]. Nanovesicles may affect these changes either directly, via the pro- and anti-inflammatory proteins carried on their surface and within their lumen, or indirectly, via the induction of inflammatory pathways in the target cells with which they engage [86].

To gain insight into the contribution of proteins packaged in extracellular vesicles, we established the profile and compartmentalization of extracellular vesicle-associated proteins in

amniotic fluid obtained from women with preterm labor. We evaluated the distribution of 38 cytokines between the vesicle surface and intra-vesicle compartments. Their concentration in extracellular vesicle-free amniotic fluid was also determined for each sample. These measurements allowed us to test whether there was an advantage to measuring cytokine concentrations in the extracellular vesicle compartments, as opposed to unfractionated amniotic fluid, in predicting preterm delivery. We have specifically addressed the following research questions:

### **Does the cytokine abundance internal to and on the extracellular vesicle surface change with sterile intra-amniotic inflammation and with intra-amniotic infection in women with preterm labor?**

We found that intra-amniotic inflammation, regardless of detected microbial invasion of the amniotic fluid cavity, was associated with an increased abundance of cytokines internal to and on the surface of extracellular vesicles. Earlier we reported on the general increase of cytokines [61] in unfractionated amniotic fluid obtained from preterm labor cases with intra-amniotic infection and sterile intra-amniotic inflammation. These results are reconfirmed herein, but here, for the first time we report on changes in cytokines quantified internally and on the surface of extracellular vesicles in this subset of women with preterm labor. Development of the pro-inflammatory vesicle surface was most evident in intra-amniotic infection, for which the surface expression of 37 cytokines was increased. Of these, 36 cytokines were also increased in the soluble fraction of amniotic fluid, and 24 had increased concentrations within the extracellular vesicles.

The extracellular vesicle associated proteins showing the strongest increase in concentration with intra-amniotic infection were MIP-3 $\alpha$ , Calgranulin C, CXCL6, ITAC/CXCL11, MCP1, MIP-1 $\alpha$ , Eotaxin 1, IL-8, Gro- $\alpha$ /CXCL1, and IL-6 on the surface, and MIP-3 $\alpha$  and Calgranulin A in the lumen. The up-regulation of these pro-inflammatory cytokines (IL-6), chemokines (MIP-3 $\alpha$ , CXCL6, ITAC/CXCL11, MCP1, MIP-1 $\alpha$ , Eotaxin 1, IL-8, Gro- $\alpha$ /CXCL1) and antimicrobial polypeptides (Calgranulin C) results from the activation of the innate immune system which includes the recognition of pathogen-associated molecular patterns (PAMPs) by pattern recognition receptors (e.g. Toll-like receptors, C-reactive protein) [61, 113, 162–167]. This is plausible given the observed increase in the concentration of the C-reactive protein (CRP) in the soluble fraction of the amniotic fluid in preterm labor with intra-amniotic infection.

The top ranked proteins based on the magnitude of change in their concentrations with sterile intra-amniotic inflammation were Calgranulin C, MIP-3 $\alpha$ , IL-16, MIP-1b, Gro $\alpha$ /CXCL1, CXCL6, MCP-1, IL-8, CXCL13, and IL-6 on the surface of extracellular vesicles and MIP-3 $\alpha$ , and Calgranulin C in the lumen of extracellular vesicles. The overexpression of these inflammatory mediators in the absence of microbes is initiated upon recognition of damage-associated molecular patterns (DAMPs or alarmins) by pattern recognition receptors (e.g. Toll-like receptors, NLRs, etc.) [61, 165, 168–171]. In this study, we observed that concentrations of alarmins, IL-1 $\alpha$  [172], and S100 family proteins (Calgranulin A, and Calgranulin C) [173] were significantly increased in the soluble fraction of the amniotic fluid in preterm labor cases with sterile intra-amniotic inflammation. These findings are in line with previous studies showing that the intra-amniotic administration of alarmins induces sterile intra-amniotic inflammation and preterm birth in mice [174, 175]. The mechanisms whereby DAMPs induce sterile intra-amniotic inflammation and preterm birth involve the activation of the NLRP3 inflammasome [99, 124, 175–179]

The association of intra-amniotic inflammation with or without detected microbes with preterm parturition syndrome and the role of cytokines in these processes are well documented



[60, 61, 93, 96, 97, 180–182]. However, this study shows that there is up-regulation in inflammatory mediators secreted not only as free molecules in amniotic fluid but also as part of the cargo carried by extracellular vesicles. The observed expression and the change in abundance of not only free (soluble) cytokines but also extracellular vesicle associated cytokines with intra-amniotic inflammation/infection may represent urgency and redundancy in the fetoplacental unit's response to environmental stimuli.

While cytokine changes with inflammation, regardless of detected microbial invasion of the amniotic fluid cavity, on the surface of extracellular vesicles correlated with those determined in the soluble fraction of amniotic fluid, the magnitude of the increase was significantly different between these compartments, suggesting that they include different information about the amniotic fluid milieu. Overall, although protein changes in extracellular vesicle surface and the soluble fraction in intra-amniotic inflammation, regardless of detected microorganisms, were higher than those within the extracellular vesicles, the magnitude of changes within the extracellular vesicles was higher compared to the soluble fraction of amniotic fluid for MIP-3 $\alpha$ .

Cytokines contained within the internal compartment are not accessible to routine immunoassay quantification; therefore, this contribution has not been incorporated in contemporary models of inflammation-associated parturition. While the relative amount of internal mediators is low, their biological effect may be significant as vesicles can deliver these mediators to the very vicinity of the target cells. The roles of these extracellular vesicle-associated mediators in parturition remain to be established. Previously, we and other investigators have established that encapsulation within extracellular vesicles protects against degradation and affords alternative pathways for engagement with target cells and transport pathways [183].

### **Is compartmentalized amniotic fluid protein concentration profiling useful in the development of biomarkers for early preterm delivery?**

To determine the potential of amniotic fluid compartmentalized protein profiling for developing new biomarkers of preterm labor and other obstetrical complications, we have developed univariate and multi-variate prediction models for early preterm delivery (gestational age  $\leq 32$  weeks). For all but one cytokine (TRAIL), the AUC estimates obtained from either the extracellular vesicle surface or the amniotic fluid soluble fraction concentrations were significantly above 0.5. The AUC statistic for univariate models based on data collected on the extracellular vesicle surface for IL-6, IL-8, MCP-1, MIP-1 $\alpha$ , and MIP-1 $\beta$  was greater than 0.8. This is consistent with our previous report of the association between unfractionated amniotic fluid concentrations of these proteins and early preterm delivery in patients diagnosed with a short cervix [62]. Although prediction performances (AUC) for individual cytokines were different between compartments, the overall performance of the multivariate models was statistically similar among the different amniotic fluid compartments. This finding can be explained in part by the redundancy of the cytokine network, but it does not preclude that compartmentalized profiling could improve prediction performance for other phenotypes.

### **Strengths and limitations**

The main strength of this study is its novelty component, which is the compartmentalized profiling of proteins in the amniotic fluid for three phenotypes of preterm labor. Another strength is the moderate sample size that enabled not only detection of differences among groups within a given compartment, but also detection of significant differences in the magnitude of changes between groups across the different compartments. The use of cross-validation to avoid overfitting in multi-variate models was also a strength of the analysis. Limitations are related to the variability in the gestational ages at sampling of amniotic fluid, and the lack of

amniotic fluid samples collected during second or early third trimester from mothers without preterm labor.

## Conclusions

The data obtained in this study are consistent with our hypothesis that amniotic fluid proteins are differentially expressed and grouped within the extracellular vesicle and soluble amniotic fluid fraction, and compartment-specific profiles characterize clinical subgroups of preterm labor. Intra-amniotic inflammation with and without detectable microorganisms was associated with the differential packaging of extracellular vesicles cytokines. Proteins packaged within the extracellular vesicles contribute to total amniotic fluid concentrations. Although the current study points to possible improvement in biomarker prediction based on compartmentalized profiling, further de-convolution of the heterogeneity of preterm labor and delivery is warranted.

## Supporting information

**S1 Fig. Box plots of transformed protein concentrations by preterm labor group and amniotic fluid compartment.** Protein concentrations were offset by adding 1 unit and then  $\log_2$  transformed before plotting. Control: preterm labor without either intra-amniotic inflammation or proven intra-amniotic infection.  
(TIFF)

**S1 Table. Protein annotation.** Full names of the 38 proteins measured on the surface and within extracellular vesicles and in the soluble fraction of amniotic fluid are listed along with official symbols ([www.uniprot.org](http://www.uniprot.org)) of the genes coding for these proteins.  
(DOCX)

**S2 Table. Microorganisms detected in the amniotic fluid.** Each line corresponds to one of the 33 patients with intra amniotic infection.  
(DOCX)

**S3 Table. Proteomic dataset.** Concentrations (pg/ml) of 38 proteins in amniotic fluid compartments (internal, surface, and soluble) for each sample (row) are provided. ID: anonymized identifier indicator of the pregnant mother, GAatAmnio: gestational age at the time of amniocentesis (weeks); GAatDelivery: gestational age at the time of delivery (weeks); Group: preterm labor subgroup where IAI refers to intra-amniotic infection and SIAI refers to sterile intra-amniotic inflammation.  
(XLSX)

**S4 Table. Detection of proteins.** The number (and the proportion) of cases where a non-zero protein concentration was detected is presented by preterm labor group and by amniotic fluid compartment. PTL: preterm labor, EV: extracellular vesicle, AF: amniotic fluid.  
(DOCX)

## Author Contributions

**Conceptualization:** Gaurav Bhatti, Roberto Romero, Gregory Edward Rice, Wendy Fitzgerald, Adi L. Tarca, Leonid Margolis.

**Data curation:** Gaurav Bhatti, Percy Pacora.

**Formal analysis:** Gaurav Bhatti.

**Funding acquisition:** Roberto Romero.

**Investigation:** Gaurav Bhatti, Gregory Edward Rice, Wendy Fitzgerald, Percy Pacora, Nardhy Gomez-Lopez, Leonid Margolis.

**Methodology:** Gaurav Bhatti, Wendy Fitzgerald, Leonid Margolis.

**Resources:** Roberto Romero.

**Supervision:** Adi L. Tarca.

**Visualization:** Gaurav Bhatti.

**Writing – original draft:** Gaurav Bhatti, Gregory Edward Rice, Leonid Margolis.

**Writing – review & editing:** Gaurav Bhatti, Roberto Romero, Gregory Edward Rice, Wendy Fitzgerald, Percy Pacora, Nardhy Gomez-Lopez, Mahendra Kavdia, Adi L. Tarca, Leonid Margolis.

## References

1. Cole CR, Hansen NI, Higgins RD, Ziegler TR, Stoll BJ, Eunice Kennedy Shriver NNRN. Very low birth weight preterm infants with surgical short bowel syndrome: incidence, morbidity and mortality, and growth outcomes at 18 to 22 months. *Pediatrics*. 2008; 122(3):e573–82. Epub 2008/09/03. <https://doi.org/10.1542/peds.2007-3449> PMID: 18762491.
2. Beck S, Wojdyla D, Say L, Betran AP, Merialdi M, Requejo JH, et al. The worldwide incidence of preterm birth: a systematic review of maternal mortality and morbidity. *Bull World Health Organ*. 2010; 88(1):31–8. Epub 2010/04/30. <https://doi.org/10.2471/BLT.08.062554> PMID: 20428351.
3. Dong Y, Yu JL. An overview of morbidity, mortality and long-term outcome of late preterm birth. *World J Pediatr*. 2011; 7(3):199–204. Epub 2011/08/09. <https://doi.org/10.1007/s12519-011-0290-8> PMID: 21822987.
4. Ruegger C, Hegglin M, Adams M, Bucher HU, Swiss Neonatal N. Population based trends in mortality, morbidity and treatment for very preterm- and very low birth weight infants over 12 years. *BMC Pediatr*. 2012; 12:17. Epub 2012/02/24. <https://doi.org/10.1186/1471-2431-12-17> PMID: 22356724.
5. Yamakawa T, Itabashi K, Kusuda S, Neonatal Research Network of J. Mortality and morbidity risks vary with birth weight standard deviation score in growth restricted extremely preterm infants. *Early Hum Dev*. 2016; 92:7–11. Epub 2015/11/30. <https://doi.org/10.1016/j.earlhumdev.2015.10.019> PMID: 26615548.
6. Fritz T, Kallen K, Marsal K, Jacobsson B. Outcome of extremely preterm infants after iatrogenic or spontaneous birth. *Acta Obstet Gynecol Scand*. 2018. Epub 2018/05/26. <https://doi.org/10.1111/aogs.13387> PMID: 29797737.
7. McGregor JA, French JI. Preterm Birth: The Role of Infection and Inflammation. *Medscape Womens Health*. 1997; 2(8):1. Epub 1997/08/01. PMID: 9746700.
8. Klebanoff M, Searle K. The role of inflammation in preterm birth—focus on periodontitis. *BJOG*. 2006; 113 Suppl 3:43–5. Epub 2007/01/09. <https://doi.org/10.1111/j.1471-0528.2006.01121.x> PMID: 17206963.
9. Romero R, Espinoza J, Goncalves LF, Kusanovic JP, Friel L, Hassan S. The role of inflammation and infection in preterm birth. *Semin Reprod Med*. 2007; 25(1):21–39. Epub 2007/01/06. <https://doi.org/10.1055/s-2006-956773> PMID: 17205421.
10. Catov JM, Bodnar LM, Ness RB, Barron SJ, Roberts JM. Inflammation and dyslipidemia related to risk of spontaneous preterm birth. *Am J Epidemiol*. 2007; 166(11):1312–9. Epub 2007/10/02. <https://doi.org/10.1093/aje/kwm273> PMID: 17906337.
11. Holst D, Garnier Y. Preterm birth and inflammation-The role of genetic polymorphisms. *Eur J Obstet Gynecol Reprod Biol*. 2008; 141(1):3–9. Epub 2008/09/12. <https://doi.org/10.1016/j.ejogrb.2008.07.020> PMID: 18783866.
12. Bastek JA, Gomez LM, Elovitz MA. The role of inflammation and infection in preterm birth. *Clin Perinatol*. 2011; 38(3):385–406. Epub 2011/09/06. <https://doi.org/10.1016/j.clp.2011.06.003> PMID: 21890015.
13. Nold C, Anton L, Brown A, Elovitz M. Inflammation promotes a cytokine response and disrupts the cervical epithelial barrier: a possible mechanism of premature cervical remodeling and preterm birth. *Am*

- J Obstet Gynecol. 2012; 206(3):208.e1–7. Epub 2012/01/31. <https://doi.org/10.1016/j.ajog.2011.12.036> PMID: 22285171.
14. Kemp MW. Preterm birth, intrauterine infection, and fetal inflammation. *Front Immunol.* 2014; 5:574. Epub 2014/12/19. <https://doi.org/10.3389/fimmu.2014.00574> PMID: 25520716.
  15. Burdet J, Rubio AP, Salazar AI, Ribeiro ML, Ibarra C, Franchi AM. Inflammation, infection and preterm birth. *Curr Pharm Des.* 2014; 20(29):4741–8. Epub 2014/03/05. <https://doi.org/10.2174/1381612820666140130202224> PMID: 24588830.
  16. Cappelletti M, Della Bella S, Ferrazzi E, Mavilio D, Divanovic S. Inflammation and preterm birth. *J Leukoc Biol.* 2016; 99(1):67–78. Epub 2015/11/06. <https://doi.org/10.1189/jlb.3MR0615-272RR> PMID: 26538528.
  17. van der Krogt L, Ridout AE, Seed PT, Shennan AH. Placental inflammation and its relationship to cervicovaginal fetal fibronectin in preterm birth. *Eur J Obstet Gynecol Reprod Biol.* 2017; 214:173–7. Epub 2017/05/24. <https://doi.org/10.1016/j.ejogrb.2017.05.001> PMID: 28535404.
  18. Romero R, Sirtori M, Oyarzun E, Avila C, Mazor M, Callahan R, et al. Infection and labor. V. Prevalence, microbiology, and clinical significance of intraamniotic infection in women with preterm labor and intact membranes. *Am J Obstet Gynecol.* 1989; 161(3):817–24. Epub 1989/09/01. [https://doi.org/10.1016/0002-9378\(89\)90409-2](https://doi.org/10.1016/0002-9378(89)90409-2) PMID: 2675611.
  19. Romero R, Shamma F, Avila C, Jimenez C, Callahan R, Nores J, et al. Infection and labor. VI. Prevalence, microbiology, and clinical significance of intraamniotic infection in twin gestations with preterm labor. *Am J Obstet Gynecol.* 1990; 163(3):757–61. Epub 1990/09/01. [https://doi.org/10.1016/0002-9378\(90\)91063-i](https://doi.org/10.1016/0002-9378(90)91063-i) PMID: 2403156.
  20. Mazor M, Hershkovitz R, Ghezzi F, Maymon E, Horowitz S, Leiberman JR. Intraamniotic infection in patients with preterm labor and twin pregnancies. *Acta Obstet Gynecol Scand.* 1996; 75(7):624–7. Epub 1996/08/01. <https://doi.org/10.3109/00016349609054686> PMID: 8822654.
  21. Chaim W, Mazor M, Wiznitzer A. The prevalence and clinical significance of intraamniotic infection with *Candida* species in women with preterm labor. *Arch Gynecol Obstet.* 1992; 251(1):9–15. Epub 1992/01/01. <https://doi.org/10.1007/bf02718273> PMID: 1550392.
  22. Mazor M, Kassis A, Horowitz S, Wiznitzer A, Kuperman O, Meril C, et al. Relationship between C-reactive protein levels and intraamniotic infection in women with preterm labor. *J Reprod Med.* 1993; 38(10):799–803. Epub 1993/10/01. PMID: 8263870.
  23. Gomez R, Romero R, Edwin SS, David C. Pathogenesis of preterm labor and preterm premature rupture of membranes associated with intraamniotic infection. *Infect Dis Clin North Am.* 1997; 11(1):135–76. Epub 1997/03/01. [https://doi.org/10.1016/s0891-5520\(05\)70347-0](https://doi.org/10.1016/s0891-5520(05)70347-0) PMID: 9067790.
  24. Hsu CD, Aversa K, Meaddough E, Lee IS, Copel JA. Elevated amniotic fluid nitric oxide metabolites and cyclic guanosine 3',5'-monophosphate in pregnant women with intraamniotic infection. *Am J Obstet Gynecol.* 1997; 177(4):793–6. Epub 1997/11/25. [https://doi.org/10.1016/s0002-9378\(97\)70270-9](https://doi.org/10.1016/s0002-9378(97)70270-9) PMID: 9369821.
  25. Newton ER, Piper J, Peairs W. Bacterial vaginosis and intraamniotic infection. *Am J Obstet Gynecol.* 1997; 176(3):672–7. Epub 1997/03/01. [https://doi.org/10.1016/s0002-9378\(97\)70568-4](https://doi.org/10.1016/s0002-9378(97)70568-4) PMID: 9077627.
  26. Hsu CD, Meaddough E, Aversa K, Copel JA. The role of amniotic fluid L-selectin, GRO-alpha, and interleukin-8 in the pathogenesis of intraamniotic infection. *Am J Obstet Gynecol.* 1998; 178(3):428–32. Epub 1998/04/16. [https://doi.org/10.1016/s0002-9378\(98\)70414-4](https://doi.org/10.1016/s0002-9378(98)70414-4) PMID: 9539502.
  27. Krohn MA, Germain M, Muhlemann K, Hickok D. Prior pregnancy outcome and the risk of intraamniotic infection in the following pregnancy. *Am J Obstet Gynecol.* 1998; 178(2):381–5. Epub 1998/03/21. [https://doi.org/10.1016/s0002-9378\(98\)80029-x](https://doi.org/10.1016/s0002-9378(98)80029-x) PMID: 9500503.
  28. Mikamo H, Kawazoe K, Sato Y, Imai A, Tamaya T. Preterm labor and bacterial intraamniotic infection: arachidonic acid liberation by phospholipase A2 of *Fusobacterium nucleatum*. *Am J Obstet Gynecol.* 1998; 179(6 Pt 1):1579–82. Epub 1998/12/17. [https://doi.org/10.1016/s0002-9378\(98\)70028-6](https://doi.org/10.1016/s0002-9378(98)70028-6) PMID: 9855600.
  29. Maymon E, Romero R, Pacora P, Gomez R, Mazor M, Edwin S, et al. A role for the 72 kDa gelatinase (MMP-2) and its inhibitor (TIMP-2) in human parturition, premature rupture of membranes and intraamniotic infection. *J Perinat Med.* 2001; 29(4):308–16. Epub 2001/09/22. <https://doi.org/10.1515/JPM.2001.044> PMID: 11565199.
  30. Kim YM, Romero R, Oh SY, Kim CJ, Kilburn BA, Armant DR, et al. Toll-like receptor 4: a potential link between “danger signals,” the innate immune system, and preeclampsia? *Am J Obstet Gynecol.* 2005; 193(3 Pt 2):921–7. Epub 2005/09/15. <https://doi.org/10.1016/j.ajog.2005.07.076> PMID: 16157088.
  31. Buhimschi IA, Zhao G, Pettker CM, Bahtiyar MO, Magloire LK, Thung S, et al. The receptor for advanced glycation end products (RAGE) system in women with intraamniotic infection and

- inflammation. *Am J Obstet Gynecol.* 2007; 196(2):181.e1–13. Epub 2007/02/20. <https://doi.org/10.1016/j.ajog.2006.09.001> PMID: 17306673.
32. Gravett MG, Adams KM, Sadowsky DW, Grosvenor AR, Witkin SS, Axthelm MK, et al. Immunomodulators plus antibiotics delay preterm delivery after experimental intraamniotic infection in a nonhuman primate model. *Am J Obstet Gynecol.* 2007; 197(5):518.e1–8. Epub 2007/11/06. <https://doi.org/10.1016/j.ajog.2007.03.064> PMID: 17980193.
  33. Romero R, Schaudinn C, Kusanovic JP, Gorur A, Gotsch F, Webster P, et al. Detection of a microbial biofilm in intraamniotic infection. *Am J Obstet Gynecol.* 2008; 198(1):135.e1–5. Epub 2008/01/02. <https://doi.org/10.1016/j.ajog.2007.11.026> PMID: 18166328.
  34. Allen-Daniels MJ, Serrano MG, Pflugner LP, Fettweis JM, Prestosa MA, Koparde VN, et al. Identification of a gene in *Mycoplasma hominis* associated with preterm birth and microbial burden in intraamniotic infection. *Am J Obstet Gynecol.* 2015; 212(6):779.e1–13. Epub 2015/02/01. <https://doi.org/10.1016/j.ajog.2015.01.032> PMID: 25637842.
  35. Gomez-Lopez N, Romero R, Xu Y, Leng Y, Garcia-Flores V, Miller D, et al. Are amniotic fluid neutrophils in women with intraamniotic infection and/or inflammation of fetal or maternal origin? *Am J Obstet Gynecol.* 2017; 217(6):693.e1–e16. Epub 2017/10/02. <https://doi.org/10.1016/j.ajog.2017.09.013> PMID: 28964823.
  36. Romero R, Brody DT, Oyarzun E, Mazor M, Wu YK, Hobbins JC, et al. Infection and labor. III. Interleukin-1: a signal for the onset of parturition. *Am J Obstet Gynecol.* 1989; 160(5 Pt 1):1117–23. Epub 1989/05/01. [https://doi.org/10.1016/0002-9378\(89\)90172-5](https://doi.org/10.1016/0002-9378(89)90172-5) PMID: 2786341.
  37. Hoffman DR, Romero R, Johnston JM. Detection of platelet-activating factor in amniotic fluid of complicated pregnancies. *Am J Obstet Gynecol.* 1990; 162(2):525–8. Epub 1990/02/01. [https://doi.org/10.1016/0002-9378\(90\)90423-5](https://doi.org/10.1016/0002-9378(90)90423-5) PMID: 2309839.
  38. Romero R, Avila C, Santhanam U, Sehgal PB. Amniotic fluid interleukin 6 in preterm labor. Association with infection. *J Clin Invest.* 1990; 85(5):1392–400. Epub 1990/05/01. <https://doi.org/10.1172/JCI114583> PMID: 2332497.
  39. Romero R, Parvizi ST, Oyarzun E, Mazor M, Wu YK, Avila C, et al. Amniotic fluid interleukin-1 in spontaneous labor at term. *J Reprod Med.* 1990; 35(3):235–8. Epub 1990/03/01. PMID: 2325034.
  40. Santhanam U, Avila C, Romero R, Viguet H, Ida N, Sakurai S, et al. Cytokines in normal and abnormal parturition: elevated amniotic fluid interleukin-6 levels in women with premature rupture of membranes associated with intrauterine infection. *Cytokine.* 1991; 3(2):155–63. Epub 1991/03/01. [https://doi.org/10.1016/1043-4666\(91\)90037-e](https://doi.org/10.1016/1043-4666(91)90037-e) PMID: 1888885.
  41. Romero R, Mazor M, Sepulveda W, Avila C, Copeland D, Williams J. Tumor necrosis factor in preterm and term labor. *Am J Obstet Gynecol.* 1992; 166(5):1576–87. Epub 1992/05/01. [https://doi.org/10.1016/0002-9378\(92\)91636-o](https://doi.org/10.1016/0002-9378(92)91636-o) PMID: 1595815.
  42. Romero R, Mazor M, Brandt F, Sepulveda W, Avila C, Cotton DB, et al. Interleukin-1 alpha and interleukin-1 beta in preterm and term human parturition. *Am J Reprod Immunol.* 1992; 27(3–4):117–23. Epub 1992/04/01. <https://doi.org/10.1111/j.1600-0897.1992.tb00737.x> PMID: 1418402.
  43. Romero R, Sepulveda W, Kenney JS, Archer LE, Allison AC, Sehgal PB. Interleukin 6 determination in the detection of microbial invasion of the amniotic cavity. *Ciba Found Symp.* 1992; 167:205–20; discussion 20–3. Epub 1992/01/01. <https://doi.org/10.1002/9780470514269.ch13> PMID: 1425014.
  44. Cherouny PH, Pankuch GA, Romero R, Botti JJ, Kuhn DC, Demers LM, et al. Neutrophil attractant/activating peptide-1/interleukin-8: association with histologic chorioamnionitis, preterm delivery, and bioactive amniotic fluid leukoattractants. *Am J Obstet Gynecol.* 1993; 169(5):1299–303. Epub 1993/11/01. [https://doi.org/10.1016/0002-9378\(93\)90297-v](https://doi.org/10.1016/0002-9378(93)90297-v) PMID: 8238198.
  45. Romero R, Yoon BH, Mazor M, Gomez R, Diamond MP, Kenney JS, et al. The diagnostic and prognostic value of amniotic fluid white blood cell count, glucose, interleukin-6, and gram stain in patients with preterm labor and intact membranes. *Am J Obstet Gynecol.* 1993; 169(4):805–16. Epub 1993/10/01. [https://doi.org/10.1016/0002-9378\(93\)90009-8](https://doi.org/10.1016/0002-9378(93)90009-8) PMID: 7694461.
  46. Romero R, Yoon BH, Kenney JS, Gomez R, Allison AC, Sehgal PB. Amniotic fluid interleukin-6 determinations are of diagnostic and prognostic value in preterm labor. *Am J Reprod Immunol.* 1993; 30(2–3):167–83. Epub 1993/09/01. <https://doi.org/10.1111/j.1600-0897.1993.tb00618.x> PMID: 8311926.
  47. Laham N, Rice GE, Bishop GJ, Ransome C, Brennecke SP. Interleukin 8 concentrations in amniotic fluid and peripheral venous plasma during human pregnancy and parturition. *Acta Endocrinol (Copenh).* 1993; 129(3):220–4. Epub 1993/09/01. <https://doi.org/10.1530/acta.0.1290220> PMID: 8212986.
  48. Greig PC, Ernest JM, Teot L, Erikson M, Talley R. Amniotic fluid interleukin-6 levels correlate with histologic chorioamnionitis and amniotic fluid cultures in patients in premature labor with intact

- membranes. *Am J Obstet Gynecol.* 1993; 169(4):1035–44. Epub 1993/10/01. [https://doi.org/10.1016/0002-9378\(93\)90050-s](https://doi.org/10.1016/0002-9378(93)90050-s) PMID: 8238116.
49. Laham N, Brennecke SP, Bendtzen K, Rice GE. Tumour necrosis factor alpha during human pregnancy and labour: maternal plasma and amniotic fluid concentrations and release from intrauterine tissues. *Eur J Endocrinol.* 1994; 131(6):607–14. Epub 1994/12/01. <https://doi.org/10.1530/eje.0.1310607> PMID: 7804444.
  50. Allbert JR, Naef RW 3rd, Perry KG Jr., Magann EF, Whitworth NS, Morrison JC. Amniotic fluid interleukin-6 and interleukin-8 levels predict the success of tocolysis in patients with preterm labor. *J Soc Gynecol Investig.* 1994; 1(4):264–8. Epub 1994/10/01. <https://doi.org/10.1177/107155769400100404> PMID: 9419782.
  51. Waring PM, Romero R, Laham N, Gomez R, Rice GE. Leukemia inhibitory factor: association with intraamniotic infection. *Am J Obstet Gynecol.* 1994; 171(5):1335–41. Epub 1994/11/01. [https://doi.org/10.1016/0002-9378\(94\)90157-0](https://doi.org/10.1016/0002-9378(94)90157-0) PMID: 7977543.
  52. Greig PC, Herbert WN, Robinette BL, Teot LA. Amniotic fluid interleukin-10 concentrations increase through pregnancy and are elevated in patients with preterm labor associated with intrauterine infection. *Am J Obstet Gynecol.* 1995; 173(4):1223–7. Epub 1995/10/01. [https://doi.org/10.1016/0002-9378\(95\)91358-0](https://doi.org/10.1016/0002-9378(95)91358-0) PMID: 7485325.
  53. Dudley DJ, Hunter C, Varner MW, Mitchell MD. Elevation of amniotic fluid interleukin-4 concentrations in women with preterm labor and chorioamnionitis. *Am J Perinatol.* 1996; 13(7):443–7. Epub 1996/10/01. <https://doi.org/10.1055/s-2007-994385> PMID: 8960615.
  54. Dudley DJ, Hunter C, Mitchell MD, Varner MW. Amniotic fluid interleukin-10 (IL-10) concentrations during pregnancy and with labor. *J Reprod Immunol.* 1997; 33(2):147–56. Epub 1997/06/01. [https://doi.org/10.1016/s0165-0378\(97\)00020-x](https://doi.org/10.1016/s0165-0378(97)00020-x) PMID: 9234213.
  55. Rivero-Marcotegui A, Larranaga-Azcarate C, Ceres-Ruiz R, Garcia-Merlo S. Polymorphonuclear elastase and interleukin-6 in amniotic fluid in preterm labor. *Clin Chem.* 1997; 43(5):857–9. Epub 1997/05/01. PMID: 9166251.
  56. Veith GL, Rice GE. Interferon gamma expression during human pregnancy and in association with labour. *Gynecol Obstet Invest.* 1999; 48(3):163–7. Epub 1999/11/05. <https://doi.org/10.1159/000010165> PMID: 10545738.
  57. Kemp B, Winkler M, Maas A, Maul H, Ruck P, Reineke T, et al. Cytokine concentrations in the amniotic fluid during parturition at term: correlation to lower uterine segment values and to labor. *Acta Obstet Gynecol Scand.* 2002; 81(10):938–42. Epub 2002/10/09. <https://doi.org/10.1034/j.1600-0412.2002.811007.x> PMID: 12366484.
  58. Jacobsson B, Mattsby-Baltzer I, Andersch B, Bokstrom H, Holst RM, Wennerholm UB, et al. Microbial invasion and cytokine response in amniotic fluid in a Swedish population of women in preterm labor. *Acta Obstet Gynecol Scand.* 2003; 82(2):120–8. Epub 2003/03/22. <https://doi.org/10.1034/j.1600-0412.2003.00047.x> PMID: 12648172.
  59. Holst RM, Mattsby-Baltzer I, Wennerholm UB, Hagberg H, Jacobsson B. Interleukin-6 and interleukin-8 in cervical fluid in a population of Swedish women in preterm labor: relationship to microbial invasion of the amniotic fluid, intra-amniotic inflammation, and preterm delivery. *Acta Obstet Gynecol Scand.* 2005; 84(6):551–7. Epub 2005/05/20. <https://doi.org/10.1111/j.0001-6349.2005.00708.x> PMID: 15901266.
  60. Combs CA, Gravett M, Garite TJ, Hickok DE, Lapidus J, Porreco R, et al. Amniotic fluid infection, inflammation, and colonization in preterm labor with intact membranes. *Am J Obstet Gynecol.* 2014; 210(2):125.e1–e15. Epub 2013/11/28. <https://doi.org/10.1016/j.ajog.2013.11.032> PMID: 24274987.
  61. Romero R, Grivel JC, Tarca AL, Chaemsaitong P, Xu Z, Fitzgerald W, et al. Evidence of perturbations of the cytokine network in preterm labor. *Am J Obstet Gynecol.* 2015; 213(6):836.e1–e18. Epub 2015/08/02. <https://doi.org/10.1016/j.ajog.2015.07.037> PMID: 26232508.
  62. Tarca AL, Fitzgerald W, Chaemsaitong P, Xu Z, Hassan SS, Grivel JC, et al. The cytokine network in women with an asymptomatic short cervix and the risk of preterm delivery. *Am J Reprod Immunol.* 2017; 78(3). <https://doi.org/10.1111/aji.12686> PMID: 28585708.
  63. Rieckmann P, D'Alessandro F, Nordan RP, Fauci AS, Kehrl JH. IL-6 and tumor necrosis factor-alpha. Autocrine and paracrine cytokines involved in B cell function. *J Immunol.* 1991; 146(10):3462–8. Epub 1991/05/15. PMID: 2026875.
  64. Cassatella MA, Meda L, Bonora S, Ceska M, Constantin G. Interleukin 10 (IL-10) inhibits the release of proinflammatory cytokines from human polymorphonuclear leukocytes. Evidence for an autocrine role of tumor necrosis factor and IL-1 beta in mediating the production of IL-8 triggered by lipopolysaccharide. *J Exp Med.* 1993; 178(6):2207–11. Epub 1993/12/01. <https://doi.org/10.1084/jem.178.6.2207> PMID: 8245792.

65. Arzt E, Stalla GK. Cytokines: autocrine and paracrine roles in the anterior pituitary. *Neuroimmunomodulation*. 1996; 3(1):28–34. Epub 1996/01/01. <https://doi.org/10.1159/000097224> PMID: [8892358](#).
66. Kaplan D. Autocrine secretion and the physiological concentration of cytokines. *Immunol Today*. 1996; 17(7):303–4. Epub 1996/07/01. [https://doi.org/10.1016/0167-5699\(96\)30017-0](https://doi.org/10.1016/0167-5699(96)30017-0) PMID: [8763813](#).
67. Renner U, Pagotto U, Arzt E, Stalla GK. Autocrine and paracrine roles of polypeptide growth factors, cytokines and vasogenic substances in normal and tumorous pituitary function and growth: a review. *Eur J Endocrinol*. 1996; 135(5):515–32. Epub 1996/11/01. <https://doi.org/10.1530/eje.0.1350515> PMID: [8980150](#).
68. Rothwell NJ. The endocrine significance of cytokines. *J Endocrinol*. 1991; 128(2):171–3. Epub 1991/02/01. <https://doi.org/10.1677/joe.0.1280171> PMID: [1900883](#).
69. Vassilopoulou-Sellin R. Endocrine effects of cytokines. *Oncology (Williston Park)*. 1994; 8(10):43–6, 9; discussion 9–50. Epub 1994/10/01. PMID: [7528526](#).
70. Silva CM, Isgaard J, Thorner MO. Cytokines in endocrine function. *Adv Protein Chem*. 1998; 52:199–221. Epub 1999/01/26. [https://doi.org/10.1016/s0065-3233\(08\)60436-2](https://doi.org/10.1016/s0065-3233(08)60436-2) PMID: [9917921](#).
71. Konadu KA, Chu J, Huang MB, Amancha PK, Armstrong W, Powell MD, et al. Association of Cytokines With Exosomes in the Plasma of HIV-1-Seropositive Individuals. *J Infect Dis*. 2015; 211(11):1712–6. Epub 2014/12/17. <https://doi.org/10.1093/infdis/jiu676> PMID: [25512626](#).
72. Tokarz A, Szuszcik I, Kusnierz-Cabala B, Kapusta M, Konkolewska M, Zurakowski A, et al. Extracellular vesicles participate in the transport of cytokines and angiogenic factors in diabetic patients with ocular complications. *Folia Med Cracov*. 2015; 55(4):35–48. Epub 2016/02/13. PMID: [26867118](#).
73. Kovach MA, Singer BH, Newstead MW, Zeng X, Moore TA, White ES, et al. IL-36gamma is secreted in microparticles and exosomes by lung macrophages in response to bacteria and bacterial components. *J Leukoc Biol*. 2016; 100(2):413–21. Epub 2016/02/13. <https://doi.org/10.1189/jlb.4A0315-087R> PMID: [26864267](#).
74. Fitzgerald W, Gomez-Lopez N, Erez O, Romero R, Margolis L. Extracellular vesicles generated by placental tissues ex vivo: A transport system for immune mediators and growth factors. *Am J Reprod Immunol*. 2018:e12860. Epub 2018/05/05. <https://doi.org/10.1111/aji.12860> PMID: [29726582](#).
75. Keller S, Rupp C, Stoeck A, Runz S, Fogel M, Lugert S, et al. CD24 is a marker of exosomes secreted into urine and amniotic fluid. *Kidney Int*. 2007; 72(9):1095–102. Epub 2007/08/19. PMID: [17700640](#).
76. Asea A, Jean-Pierre C, Kaur P, Rao P, Linhares IM, Skupski D, et al. Heat shock protein-containing exosomes in mid-trimester amniotic fluids. *J Reprod Immunol*. 2008; 79(1):12–7. Epub 2008/08/22. <https://doi.org/10.1016/j.jri.2008.06.001> PMID: [18715652](#).
77. Xiao GY, Cheng CC, Chiang YS, Cheng WT, Liu IH, Wu SC. Exosomal miR-10a derived from amniotic fluid stem cells preserves ovarian follicles after chemotherapy. *Sci Rep*. 2016; 6:23120. Epub 2016/03/17. <https://doi.org/10.1038/srep23120> PMID: [26979400](#).
78. Sedrakyan S, Villani V, Da Sacco S, Tripuraneni N, Porta S, Aghena A, et al. Amniotic fluid stem cell-derived vesicles protect from VEGF-induced endothelial damage. *Sci Rep*. 2017; 7(1):16875. Epub 2017/12/06. <https://doi.org/10.1038/s41598-017-17061-2> PMID: [29203902](#).
79. Mellows B, Mitchell R, Antonioli M, Kretz O, Chambers D, Zeuner MT, et al. Protein and Molecular Characterization of a Clinically Compliant Amniotic Fluid Stem Cell-Derived Extracellular Vesicle Fraction Capable of Accelerating Muscle Regeneration Through Enhancement of Angiogenesis. *Stem Cells Dev*. 2017; 26(18):1316–33. Epub 2017/07/07. <https://doi.org/10.1089/scd.2017.0089> PMID: [28679310](#).
80. Hell L, Wisgrill L, Ay C, Spittler A, Schwameis M, Jilma B, et al. Procoagulant extracellular vesicles in amniotic fluid. *Transl Res*. 2017; 184:12–20 e1. Epub 2017/02/27. <https://doi.org/10.1016/j.trsl.2017.01.003> PMID: [28236427](#).
81. Balbi C, Piccoli M, Barile L, Papait A, Armirotti A, Principi E, et al. First Characterization of Human Amniotic Fluid Stem Cell Extracellular Vesicles as a Powerful Paracrine Tool Endowed with Regenerative Potential. *Stem Cells Transl Med*. 2017; 6(5):1340–55. Epub 2017/03/09. <https://doi.org/10.1002/sctm.16-0297> PMID: [28271621](#).
82. Radeghieri A, Savio G, Zandrini A, Di Noto G, Salvi A, Bergese P, et al. Cultured human amniocytes express hTERT, which is distributed between nucleus and cytoplasm and is secreted in extracellular vesicles. *Biochem Biophys Res Commun*. 2017; 483(1):706–11. Epub 2016/12/19. <https://doi.org/10.1016/j.bbrc.2016.12.077> PMID: [27988335](#).
83. Zhao B, Zhang Y, Han S, Zhang W, Zhou Q, Guan H, et al. Exosomes derived from human amniotic epithelial cells accelerate wound healing and inhibit scar formation. *J Mol Histol*. 2017; 48(2):121–32. Epub 2017/02/24. <https://doi.org/10.1007/s10735-017-9711-x> PMID: [28229263](#).

84. Sheller-Miller S, Urrabaz-Garza R, Saade G, Menon R. Damage-Associated molecular pattern markers HMGB1 and cell-Free fetal telomere fragments in oxidative-Stressed amnion epithelial cell-Derived exosomes. *J Reprod Immunol*. 2017; 123:3–11. Epub 2017/09/01. <https://doi.org/10.1016/j.jri.2017.08.003> PMID: 28858636.
85. Song JE, Park SJ, Lee KY, Lee WJ. Amniotic fluid HIF1alpha and exosomal HIF1alpha in cervical insufficiency patients with physical examination-indicated cerclage. *J Matern Fetal Neonatal Med*. 2018:1–8. Epub 2018/01/24. <https://doi.org/10.1080/14767058.2018.1432037> PMID: 29357727.
86. Dixon CL, Sheller-Miller S, Saade GR, Fortunato SJ, Lai A, Palma C, et al. Amniotic Fluid Exosome Proteomic Profile Exhibits Unique Pathways of Term and Preterm Labor. *Endocrinology*. 2018; 159(5):2229–40. Epub 2018/04/11. <https://doi.org/10.1210/en.2018-00073> PMID: 29635386.
87. Beretti F, Zavatti M, Casciaro F, Comitini G, Franchi F, Barbieri V, et al. Amniotic fluid stem cell exosomes: Therapeutic perspective. *Biofactors*. 2018; 44(2):158–67. Epub 2018/01/18. <https://doi.org/10.1002/biof.1407> PMID: 29341292.
88. Farhadhosseinabadi B, Farahani M, Tayebi T, Jafari A, Biniadhan F, Modaresifar K, et al. Amniotic membrane and its epithelial and mesenchymal stem cells as an appropriate source for skin tissue engineering and regenerative medicine. *Artif Cells Nanomed Biotechnol*. 2018:1–10. Epub 2018/04/25. <https://doi.org/10.1080/21691401.2018.1458730> PMID: 29687742.
89. Tan JL, Lau SN, Leaw B, Nguyen HPT, Salamonsen LA, Saad MI, et al. Amnion Epithelial Cell-Derived Exosomes Restrict Lung Injury and Enhance Endogenous Lung Repair. *Stem Cells Transl Med*. 2018; 7(2):180–96. Epub 2018/01/04. <https://doi.org/10.1002/sctm.17-0185> PMID: 29297621.
90. Sheller S, Papaconstantinou J, Urrabaz-Garza R, Richardson L, Saade G, Salomon C, et al. Amnion-Epithelial-Cell-Derived Exosomes Demonstrate Physiologic State of Cell under Oxidative Stress. *PLoS One*. 2016; 11(6):e0157614. Epub 2016/06/23. <https://doi.org/10.1371/journal.pone.0157614> PMID: 27333275.
91. American College of O, Gynecology Committee on Practice B-O. ACOG Practice Bulletin Number 49, December 2003: Dystocia and augmentation of labor. *Obstet Gynecol*. 2003; 102(6):1445–54. Epub 2003/12/10. <https://doi.org/10.1016/j.obstetgynecol.2003.10.011> PMID: 14662243.
92. Yoon BH, Romero R, Moon JB, Shim SS, Kim M, Kim G, et al. Clinical significance of intra-amniotic inflammation in patients with preterm labor and intact membranes. *Am J Obstet Gynecol*. 2001; 185(5):1130–6. Epub 2001/11/22. <https://doi.org/10.1067/mob.2001.117680> PMID: 11717646.
93. Romero R, Chaemsaihong P, Chaiyasit N, Docheva N, Dong Z, Kim CJ, et al. CXCL10 and IL-6: Markers of two different forms of intra-amniotic inflammation in preterm labor. *Am J Reprod Immunol*. 2017; 78(1). Epub 2017/05/26. <https://doi.org/10.1111/aji.12685> PMID: 28544362.
94. Romero R, Ghidini A, Mazor M, Behnke E. Microbial invasion of the amniotic cavity in premature rupture of membranes. *Clin Obstet Gynecol*. 1991; 34(4):769–78. Epub 1991/12/01. <https://doi.org/10.1097/00003081-199112000-00013> PMID: 1778019.
95. Romero R, Nores J, Mazor M, Sepulveda W, Oyarzun E, Parra M, et al. Microbial invasion of the amniotic cavity during term labor. Prevalence and clinical significance. *J Reprod Med*. 1993; 38(7):543–8. Epub 1993/07/01. PMID: 8410850.
96. Romero R, Miranda J, Chaiworapongsa T, Korzeniewski SJ, Chaemsaihong P, Gotsch F, et al. Prevalence and clinical significance of sterile intra-amniotic inflammation in patients with preterm labor and intact membranes. *Am J Reprod Immunol*. 2014; 72(5):458–74. Epub 2014/08/01. <https://doi.org/10.1111/aji.12296> PMID: 25078709.
97. Romero R, Miranda J, Chaemsaihong P, Chaiworapongsa T, Kusanovic JP, Dong Z, et al. Sterile and microbial-associated intra-amniotic inflammation in preterm prelabor rupture of membranes. *J Matern Fetal Neonatal Med*. 2015; 28(12):1394–409. Epub 2014/09/06. <https://doi.org/10.3109/14767058.2014.958463> PMID: 25190175.
98. Romero R, Miranda J, Chaiworapongsa T, Chaemsaihong P, Gotsch F, Dong Z, et al. Sterile intra-amniotic inflammation in asymptomatic patients with a sonographic short cervix: prevalence and clinical significance. *J Matern Fetal Neonatal Med*. 2015; 28(11):1343–59. Epub 2014/09/06. <https://doi.org/10.3109/14767058.2014.954243> PMID: 25123515.
99. Gomez-Lopez N, Romero R, Panaitescu B, Leng Y, Xu Y, Tarca AL, et al. Inflammasome activation during spontaneous preterm labor with intra-amniotic infection or sterile intra-amniotic inflammation. *Am J Reprod Immunol*. 2018; 80(5):e13049. Epub 2018/11/10. <https://doi.org/10.1111/aji.13049> PMID: 30225853.
100. Gomez-Lopez N, Romero R, Tarca AL, Miller D, Panaitescu B, Schwenkel G, et al. Gasdermin D: Evidence of Pyroptosis in Spontaneous Preterm Labor with Sterile Intra-amniotic Inflammation or Intra-amniotic Infection. *Am J Reprod Immunol*. 2019. Epub 2019/08/29. <https://doi.org/10.1111/aji.13184> PMID: 31461796.



101. Gomez-Lopez N, Romero R, Maymon E, Kusanovic JP, Panaitescu B, Miller D, et al. Clinical chorioamnionitis at term IX: in vivo evidence of intra-amniotic inflammasome activation. *J Perinat Med*. 2019; 47(3):276–87. Epub 2018/11/10. <https://doi.org/10.1515/jpm-2018-0271> PMID: 30412466.
102. Romero R, Quintero R, Nores J, Avila C, Mazor M, Hanaoka S, et al. Amniotic fluid white blood cell count: a rapid and simple test to diagnose microbial invasion of the amniotic cavity and predict preterm delivery. *Am J Obstet Gynecol*. 1991; 165(4 Pt 1):821–30. Epub 1991/10/01. [https://doi.org/10.1016/0002-9378\(91\)90423-o](https://doi.org/10.1016/0002-9378(91)90423-o) PMID: 1951538.
103. Martinez-Varea A, Romero R, Xu Y, Miller D, Ahmed AI, Chaemsaitong P, et al. Clinical chorioamnionitis at term VII: the amniotic fluid cellular immune response. *J Perinat Med*. 2017; 45(5):523–38. Epub 2016/10/21. <https://doi.org/10.1515/jpm-2016-0225> PMID: 27763883.
104. Romero R, Jimenez C, Lohda AK, Nores J, Hanaoka S, Avila C, et al. Amniotic fluid glucose concentration: a rapid and simple method for the detection of intraamniotic infection in preterm labor. *Am J Obstet Gynecol*. 1990; 163(3):968–74. Epub 1990/09/01. [https://doi.org/10.1016/0002-9378\(90\)91106-m](https://doi.org/10.1016/0002-9378(90)91106-m) PMID: 1698338.
105. Romero R, Emamian M, Quintero R, Wan M, Hobbins JC, Mazor M, et al. The value and limitations of the Gram stain examination in the diagnosis of intraamniotic infection. *Am J Obstet Gynecol*. 1988; 159(1):114–9. Epub 1988/07/01. [https://doi.org/10.1016/0002-9378\(88\)90503-0](https://doi.org/10.1016/0002-9378(88)90503-0) PMID: 2456013.
106. Welch BL. On the Comparison of Several Mean Values: An Alternative Approach. *Biometrika*. 1951; 38(3/4):330–6. <https://doi.org/10.2307/2332579>
107. Bartlett MS. The Use of Transformations. *Biometrics*. 1947; 3(1):39–52. <https://doi.org/10.2307/3001536> PMID: 20240416
108. Koenker R. Quantile regression for longitudinal data. *Journal of Multivariate Analysis*. 2004; 91(1):74–89. <https://doi.org/10.1016/j.jmva.2004.05.006>
109. Benjamini Y, Hochberg Y. Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing. *Journal of the Royal Statistical Society Series B (Methodological)*. 1995; 57(1):289–300.
110. R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2019.
111. Chen C, Liaw A, Breiman L. Using random forest to learn imbalanced data. Technical report. Berkeley: University of California, 2004.
112. Martin JA, Hamilton BE, Osterman MJK, Driscoll AK, Drake P. Births: Final Data for 2017. *National Vital Statistics Reports*. 2018; 67(8). PMID: 30707672
113. Romero R, Espinoza J, Kusanovic JP, Gotsch F, Hassan S, Erez O, et al. The preterm parturition syndrome. *BJOG*. 2006; 113 Suppl 3:17–42. Epub 2007/01/09. <https://doi.org/10.1111/j.1471-0528.2006.01120.x> PMID: 17206962.
114. Romero R. Prenatal medicine: the child is the father of the man. 1996. *J Matern Fetal Neonatal Med*. 2009; 22(8):636–9. Epub 2009/09/09. <https://doi.org/10.1080/14767050902784171> PMID: 19736614.
115. Di Renzo GC. The great obstetrical syndromes. *J Matern Fetal Neonatal Med*. 2009; 22(8):633–5. Epub 2009/09/09. <https://doi.org/10.1080/14767050902866804> PMID: 19736613.
116. Gravett MG, Novy MJ, Rosenfeld RG, Reddy AP, Jacob T, Turner M, et al. Diagnosis of intra-amniotic infection by proteomic profiling and identification of novel biomarkers. *Jama*. 2004; 292(4):462–9. Epub 2004/07/29. <https://doi.org/10.1001/jama.292.4.462> PMID: 15280344.
117. Romero R, Kusanovic JP, Gotsch F, Erez O, Vaisbuch E, Mazaki-Tovi S, et al. Isobaric labeling and tandem mass spectrometry: a novel approach for profiling and quantifying proteins differentially expressed in amniotic fluid in preterm labor with and without intra-amniotic infection/inflammation. *J Matern Fetal Neonatal Med*. 2010; 23(4):261–80. Epub 2009/08/12. <https://doi.org/10.3109/14767050903067386> PMID: 19670042.
118. Romero R, Chaiworapongsa T, Savasan ZA, Hussein Y, Dong Z, Kusanovic JP, et al. Clinical chorioamnionitis is characterized by changes in the expression of the alarmin HMGB1 and one of its receptors, sRAGE. *J Matern Fetal Neonatal Med*. 2012; 25(6):558–67. Epub 2012/05/15. <https://doi.org/10.3109/14767058.2011.599083> PMID: 22578261.
119. Romero R, Chaemsaitong P, Korzeniewski SJ, Tarca AL, Bhatti G, Xu Z, et al. Clinical chorioamnionitis at term II: the intra-amniotic inflammatory response. *J Perinat Med*. 2016; 44(1):5–22. Epub 2015/05/06. <https://doi.org/10.1515/jpm-2015-0045> PMID: 25938217.
120. Maddipati KR, Romero R, Chaiworapongsa T, Chaemsaitong P, Zhou SL, Xu Z, et al. Clinical chorioamnionitis at term: the amniotic fluid fatty acyl lipidome. *Journal of lipid research*. 2016; 57(10):1906–16. Epub 2016/08/20. <https://doi.org/10.1194/jlr.P069096> PMID: 27538821.
121. Maddipati KR, Romero R, Chaiworapongsa T, Chaemsaitong P, Zhou SL, Xu Z, et al. Lipidomic analysis of patients with microbial invasion of the amniotic cavity reveals up-regulation of leukotriene B4.

- FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2016; 30(10):3296–307. Epub 2016/06/18. <https://doi.org/10.1096/fj.201600583R> PMID: 27312808.
122. Romero R, Chaemsaitong P, Docheva N, Korzeniewski SJ, Kusanovic JP, Yoon BH, et al. Clinical chorioamnionitis at term VI: acute chorioamnionitis and funisitis according to the presence or absence of microorganisms and inflammation in the amniotic cavity. *J Perinat Med.* 2016; 44(1):33–51. Epub 2015/09/10. <https://doi.org/10.1515/jpm-2015-0119> PMID: 26352071.
  123. Romero R, Chaemsaitong P, Docheva N, Korzeniewski SJ, Tarca AL, Bhatti G, et al. Clinical chorioamnionitis at term V: umbilical cord plasma cytokine profile in the context of a systemic maternal inflammatory response. *J Perinat Med.* 2016; 44(1):53–76. Epub 2015/09/12. <https://doi.org/10.1515/jpm-2015-0121> PMID: 26360486.
  124. Gomez-Lopez N, Romero R, Xu Y, Plazyo O, Unkel R, Leng Y, et al. A Role for the Inflammasome in Spontaneous Preterm Labor With Acute Histologic Chorioamnionitis. *Reprod Sci.* 2017; 24(10):1382–401. Epub 2017/01/27. <https://doi.org/10.1177/1933719116687656> PMID: 28122480.
  125. Chaiyasit N, Romero R, Chaemsaitong P, Docheva N, Bhatti G, Kusanovic JP, et al. Clinical chorioamnionitis at term VIII: a rapid MMP-8 test for the identification of intra-amniotic inflammation. *J Perinat Med.* 2017; 45(5):539–50. Epub 2017/07/05. <https://doi.org/10.1515/jpm-2016-0344> PMID: 28672752.
  126. Gomez-Lopez N, Romero R, Xu Y, Miller D, Unkel R, Shaman M, et al. Neutrophil Extracellular Traps in the Amniotic Cavity of Women with Intra-Amniotic Infection: A New Mechanism of Host Defense. *Reprod Sci.* 2017; 24(8):1139–53. Epub 2017/07/05. <https://doi.org/10.1177/1933719116678690> PMID: 27884950.
  127. Gomez-Lopez N, Romero R, Leng Y, Xu Y, Slutsky R, Levenson D, et al. The origin of amniotic fluid monocytes/macrophages in women with intra-amniotic inflammation or infection. *J Perinat Med.* 2019. Epub 2019/09/09. <https://doi.org/10.1515/jpm-2019-0262> PMID: 31494640.
  128. Para R, Romero R, Miller D, Panaitescu B, Varrey A, Chaiworapongsa T, et al. Human beta-defensin-3 participates in intra-amniotic host defense in women with labor at term, spontaneous preterm labor and intact membranes, and preterm prelabor rupture of membranes. *J Matern Fetal Neonatal Med.* 2019:1–16. Epub 2019/04/20. <https://doi.org/10.1080/14767058.2019.1597047> PMID: 30999788.
  129. Pitt JM, Kroemer G, Zitvogel L. Extracellular vesicles: masters of intercellular communication and potential clinical interventions. *J Clin Invest.* 2016; 126(4):1139–43. <https://doi.org/10.1172/JCI87316> PMID: 27035805.
  130. Meldolesi J. Exosomes and Ectosomes in Intercellular Communication. *Curr Biol.* 2018; 28(8):R435–R44. Epub 2018/04/25. <https://doi.org/10.1016/j.cub.2018.01.059> PMID: 29689228.
  131. Soler N, Marguet E, Verbavatz JM, Forterre P. Virus-like vesicles and extracellular DNA produced by hyperthermophilic archaea of the order Thermococcales. *Res Microbiol.* 2008; 159(5):390–9. Epub 2008/07/16. <https://doi.org/10.1016/j.resmic.2008.04.015> PMID: 18625304.
  132. Schorey JS, Cheng Y, Singh PP, Smith VL. Exosomes and other extracellular vesicles in host-pathogen interactions. *EMBO Rep.* 2015; 16(1):24–43. Epub 2014/12/10. <https://doi.org/10.15252/embr.201439363> PMID: 25488940.
  133. Halperin W, Jensen WA. Ultrastructural changes during growth and embryogenesis in carrot cell cultures. *J Ultrastruct Res.* 1967; 18(3):428–43. Epub 1967/05/01. [https://doi.org/10.1016/s0022-5320\(67\)80128-x](https://doi.org/10.1016/s0022-5320(67)80128-x) PMID: 6025110.
  134. Meyer D, Pajonk S, Micali C, O'Connell R, Schulze-Lefert P. Extracellular transport and integration of plant secretory proteins into pathogen-induced cell wall compartments. *Plant J.* 2009; 57(6):986–99. Epub 2008/11/13. <https://doi.org/10.1111/j.1365-313X.2008.03743.x> PMID: 19000165.
  135. Regente M, Corti-Monzon G, Maldonado AM, Pinedo M, Jorin J, de la Canal L. Vesicular fractions of sunflower apoplast fluids are associated with potential exosome marker proteins. *FEBS Lett.* 2009; 583(20):3363–6. Epub 2009/10/03. <https://doi.org/10.1016/j.febslet.2009.09.041> PMID: 19796642.
  136. Rutter BD, Innes RW. Extracellular Vesicles Isolated from the Leaf Apoplast Carry Stress-Response Proteins. *Plant Physiol.* 2017; 173(1):728–41. Epub 2016/11/12. <https://doi.org/10.1104/pp.16.01253> PMID: 27837092.
  137. Regente M, Pinedo M, San Clemente H, Balliau T, Jamet E, de la Canal L. Plant extracellular vesicles are incorporated by a fungal pathogen and inhibit its growth. *J Exp Bot.* 2017; 68(20):5485–95. Epub 2017/11/18. <https://doi.org/10.1093/jxb/erx355> PMID: 29145622.
  138. Cocucci E, Meldolesi J. Ectosomes and exosomes: shedding the confusion between extracellular vesicles. *Trends Cell Biol.* 2015; 25(6):364–72. Epub 2015/02/17. <https://doi.org/10.1016/j.tcb.2015.01.004> PMID: 25683921.
  139. Margolis L, Sadovsky Y. The biology of extracellular vesicles: The known unknowns. *PLoS Biol.* 2019; 17(7):e3000363–e. <https://doi.org/10.1371/journal.pbio.3000363> PMID: 31318874.

140. Skog J, Würdinger T, van Rijn S, Meijer DH, Gainche L, Sena-Esteves M, et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. *Nat Cell Biol.* 2008; 10(12):1470–6. Epub 11/16. <https://doi.org/10.1038/ncb1800> PMID: [19011622](https://pubmed.ncbi.nlm.nih.gov/19011622/).
141. Valadi H, Ekstrom K, Bossios A, Sjostrand M, Lee JJ, Lotvall JO. Exosome-mediated transfer of mRNAs and microRNAs is a novel mechanism of genetic exchange between cells. *Nat Cell Biol.* 2007; 9(6):654–9. Epub 2007/05/09. <https://doi.org/10.1038/ncb1596> PMID: [17486113](https://pubmed.ncbi.nlm.nih.gov/17486113/).
142. Thakur BK, Zhang H, Becker A, Matei I, Huang Y, Costa-Silva B, et al. Double-stranded DNA in exosomes: a novel biomarker in cancer detection. *Cell Res.* 2014; 24(6):766–9. Epub 04/08. <https://doi.org/10.1038/cr.2014.44> PMID: [24710597](https://pubmed.ncbi.nlm.nih.gov/24710597/).
143. Eken C, Gasser O, Zenhausern G, Oehri I, Hess C, Schifferli JA. Polymorphonuclear neutrophil-derived ectosomes interfere with the maturation of monocyte-derived dendritic cells. *J Immunol.* 2008; 180(2):817–24. Epub 2008/01/08. <https://doi.org/10.4049/jimmunol.180.2.817> PMID: [18178820](https://pubmed.ncbi.nlm.nih.gov/18178820/).
144. Sadallah S, Eken C, Schifferli JA. Erythrocyte-derived ectosomes have immunosuppressive properties. *J Leukoc Biol.* 2008; 84(5):1316–25. Epub 2008/08/08. <https://doi.org/10.1189/jlb.0108013> PMID: [18685086](https://pubmed.ncbi.nlm.nih.gov/18685086/).
145. Eken C, Martin PJ, Sadallah S, Treves S, Schaller M, Schifferli JA. Ectosomes released by polymorphonuclear neutrophils induce a MerTK-dependent anti-inflammatory pathway in macrophages. *J Biol Chem.* 2010; 285(51):39914–21. Epub 2010/10/21. <https://doi.org/10.1074/jbc.M110.126748> PMID: [20959443](https://pubmed.ncbi.nlm.nih.gov/20959443/).
146. Sadallah S, Eken C, Martin PJ, Schifferli JA. Microparticles (ectosomes) shed by stored human platelets downregulate macrophages and modify the development of dendritic cells. *J Immunol.* 2011; 186(11):6543–52. Epub 2011/04/29. <https://doi.org/10.4049/jimmunol.1002788> PMID: [21525379](https://pubmed.ncbi.nlm.nih.gov/21525379/).
147. Sadallah S, Eken C, Schifferli JA. Ectosomes as immunomodulators. *Semin Immunopathol.* 2011; 33(5):487–95. Epub 2010/12/08. <https://doi.org/10.1007/s00281-010-0232-x> PMID: [21136061](https://pubmed.ncbi.nlm.nih.gov/21136061/).
148. Eken C, Sadallah S, Martin PJ, Treves S, Schifferli JA. Ectosomes of polymorphonuclear neutrophils activate multiple signaling pathways in macrophages. *Immunobiology.* 2013; 218(3):382–92. Epub 2012/07/04. <https://doi.org/10.1016/j.imbio.2012.05.021> PMID: [22749214](https://pubmed.ncbi.nlm.nih.gov/22749214/).
149. Dujardin S, Begard S, Cailliez R, Lachaud C, Delattre L, Carrier S, et al. Ectosomes: a new mechanism for non-exosomal secretion of tau protein. *PLoS One.* 2014; 9(6):e100760. Epub 2014/06/28. <https://doi.org/10.1371/journal.pone.0100760> PMID: [24971751](https://pubmed.ncbi.nlm.nih.gov/24971751/).
150. Ti D, Hao H, Tong C, Liu J, Dong L, Zheng J, et al. LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b. *J Transl Med.* 2015; 13:308. Epub 2015/09/21. <https://doi.org/10.1186/s12967-015-0642-6> PMID: [26386558](https://pubmed.ncbi.nlm.nih.gov/26386558/).
151. Essandoh K, Yang L, Wang X, Huang W, Qin D, Hao J, et al. Blockade of exosome generation with GW4869 dampens the sepsis-induced inflammation and cardiac dysfunction. *Biochim Biophys Acta.* 2015; 1852(11):2362–71. Epub 2015/08/25. <https://doi.org/10.1016/j.bbadis.2015.08.010> PMID: [26300484](https://pubmed.ncbi.nlm.nih.gov/26300484/).
152. Li X, Liu L, Yang J, Yu Y, Chai J, Wang L, et al. Exosome Derived From Human Umbilical Cord Mesenchymal Stem Cell Mediates MiR-181c Attenuating Burn-induced Excessive Inflammation. *EBioMedicine.* 2016; 8:72–82. Epub 2016/07/20. <https://doi.org/10.1016/j.ebiom.2016.04.030> PMID: [27428420](https://pubmed.ncbi.nlm.nih.gov/27428420/).
153. Sadallah S, Schmied L, Eken C, Charoudeh HN, Amicarella F, Schifferli JA. Platelet-Derived Ectosomes Reduce NK Cell Function. *J Immunol.* 2016; 197(5):1663–71. Epub 2016/07/28. <https://doi.org/10.4049/jimmunol.1502658> PMID: [27448586](https://pubmed.ncbi.nlm.nih.gov/27448586/).
154. Alexander M, Ramstead AG, Bauer KM, Lee SH, Runtsch MC, Wallace J, et al. Rab27-Dependent Exosome Production Inhibits Chronic Inflammation and Enables Acute Responses to Inflammatory Stimuli. *J Immunol.* 2017; 199(10):3559–70. Epub 2017/10/06. <https://doi.org/10.4049/jimmunol.1700904> PMID: [28978688](https://pubmed.ncbi.nlm.nih.gov/28978688/).
155. Tan DBA, Armitage J, Teo TH, Ong NE, Shin H, Moodley YP. Elevated levels of circulating exosome in COPD patients are associated with systemic inflammation. *Respir Med.* 2017; 132:261–4. Epub 2017/05/10. <https://doi.org/10.1016/j.rmed.2017.04.014> PMID: [28476471](https://pubmed.ncbi.nlm.nih.gov/28476471/).
156. Olmos-Ortiz LM, Barajas-Mendiola MA, Barrios-Rodiles M, Castellano LE, Arias-Negrete S, Avila EE, et al. *Trichomonas vaginalis* exosome-like vesicles modify the cytokine profile and reduce inflammation in parasite-infected mice. *Parasite Immunol.* 2017; 39(6). Epub 2017/03/28. <https://doi.org/10.1111/pim.12426> PMID: [28345149](https://pubmed.ncbi.nlm.nih.gov/28345149/).
157. Li P, Liu Z, Xie Y, Gu H, Dai Q, Yao J, et al. Serum Exosomes Attenuate H2O2-Induced Apoptosis in Rat H9C2 Cardiomyocytes via ERK1/2. *J Cardiovasc Transl Res.* 2018. Epub 2018/02/07. <https://doi.org/10.1007/s12265-018-9791-3> PMID: [29404859](https://pubmed.ncbi.nlm.nih.gov/29404859/).
158. Li Y, Liu Y, Xiu F, Wang J, Cong H, He S, et al. Characterization of exosomes derived from *Toxoplasma gondii* and their functions in modulating immune responses. *Int J Nanomedicine.* 2018; 13:467–77. Epub 2018/02/07. <https://doi.org/10.2147/IJN.S151110> PMID: [29403276](https://pubmed.ncbi.nlm.nih.gov/29403276/).

159. Keller S, Ridinger J, Rupp AK, Janssen JW, Altevogt P. Body fluid derived exosomes as a novel template for clinical diagnostics. *J Transl Med.* 2011; 9:86. Epub 2011/06/10. <https://doi.org/10.1186/1479-5876-9-86> PMID: [21651777](https://pubmed.ncbi.nlm.nih.gov/21651777/).
160. Bretz NP, Ridinger J, Rupp AK, Rimbach K, Keller S, Rupp C, et al. Body fluid exosomes promote secretion of inflammatory cytokines in monocytic cells via Toll-like receptor signaling. *J Biol Chem.* 2013; 288(51):36691–702. Epub 2013/11/15. <https://doi.org/10.1074/jbc.M113.512806> PMID: [24225954](https://pubmed.ncbi.nlm.nih.gov/24225954/).
161. Sheller-Miller S, Lei J, Saade G, Salomon C, Burd I, Menon R. Feto-Maternal Trafficking of Exosomes in Murine Pregnancy Models. *Front Pharmacol.* 2016; 7:432. Epub 2016/11/30. <https://doi.org/10.3389/fphar.2016.00432> PMID: [27895585](https://pubmed.ncbi.nlm.nih.gov/27895585/).
162. Hirsch E, Wang H. The molecular pathophysiology of bacterially induced preterm labor: insights from the murine model. *J Soc Gynecol Investig.* 2005; 12(3):145–55. Epub 2005/03/24. <https://doi.org/10.1016/j.jsqi.2005.01.007> PMID: [15784499](https://pubmed.ncbi.nlm.nih.gov/15784499/).
163. Hargreaves DC, Medzhitov R. Innate Sensors of Microbial Infection. *Journal of Clinical Immunology.* 2005; 25(6):503–10. <https://doi.org/10.1007/s10875-005-8065-4> PMID: [16380814](https://pubmed.ncbi.nlm.nih.gov/16380814/)
164. Ilievski V, Lu SJ, Hirsch E. Activation of toll-like receptors 2 or 3 and preterm delivery in the mouse. *Reprod Sci.* 2007; 14(4):315–20. Epub 2007/07/24. <https://doi.org/10.1177/1933719107302959> PMID: [17644803](https://pubmed.ncbi.nlm.nih.gov/17644803/).
165. Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. *J Leukoc Biol.* 2007; 81(1):1–5. Epub 2006/10/13. <https://doi.org/10.1189/jlb.0306164> PMID: [17032697](https://pubmed.ncbi.nlm.nih.gov/17032697/).
166. Gilliaux C, Mehats C, Vaiman D, Cabrol D, Breuille-Fouche M. Functional screening of TLRs in human amniotic epithelial cells. *J Immunol.* 2011; 187(5):2766–74. Epub 2011/07/22. <https://doi.org/10.4049/jimmunol.1100217> PMID: [21775685](https://pubmed.ncbi.nlm.nih.gov/21775685/).
167. Triantafilou M, De Glanville B, Aboklaish AF, Spiller OB, Kotecha S, Triantafilou K. Synergic activation of toll-like receptor (TLR) 2/6 and 9 in response to *Ureaplasma parvum* & *urealyticum* in human amniotic epithelial cells. *PLoS One.* 2013; 8(4):e61199. <https://doi.org/10.1371/journal.pone.0061199> PMID: [23593431](https://pubmed.ncbi.nlm.nih.gov/23593431/).
168. Lotze MT, Zeh HJ, Rubartelli A, Sparvero LJ, Amoscato AA, Washburn NR, et al. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. *Immunol Rev.* 2007; 220:60–81. Epub 2007/11/06. <https://doi.org/10.1111/j.1600-065X.2007.00579.x> PMID: [17979840](https://pubmed.ncbi.nlm.nih.gov/17979840/).
169. Bianchi R, Adami C, Giambanco I, Donato R. S100B binding to RAGE in microglia stimulates COX-2 expression. *J Leukoc Biol.* 2007; 81(1):108–18. Epub 2006/10/07. <https://doi.org/10.1189/jlb.0306198> PMID: [17023559](https://pubmed.ncbi.nlm.nih.gov/17023559/).
170. Romero R, Espinoza J, Hassan S, Gotsch F, Kusanovic JP, Avila C, et al. Soluble receptor for advanced glycation end products (sRAGE) and endogenous secretory RAGE (esRAGE) in amniotic fluid: modulation by infection and inflammation. *J Perinat Med.* 2008; 36(5):388–98. <https://doi.org/10.1515/JPM.2008.076> PMID: [18593373](https://pubmed.ncbi.nlm.nih.gov/18593373/).
171. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. *Nat Rev Immunol.* 2010; 10(12):826–37. <https://doi.org/10.1038/nri2873> PMID: [21088683](https://pubmed.ncbi.nlm.nih.gov/21088683/).
172. Eigenbrod T, Park JH, Harder J, Iwakura Y, Nunez G. Cutting edge: critical role for mesothelial cells in necrosis-induced inflammation through the recognition of IL-1 alpha released from dying cells. *J Immunol.* 2008; 181(12):8194–8. <https://doi.org/10.4049/jimmunol.181.12.8194> PMID: [19050234](https://pubmed.ncbi.nlm.nih.gov/19050234/).
173. Foell D, Wittkowski H, Vogl T, Roth J. S100 proteins expressed in phagocytes: a novel group of damage-associated molecular pattern molecules. *J Leukoc Biol.* 2007; 81(1):28–37. Epub 2006/09/01. <https://doi.org/10.1189/jlb.0306170> PMID: [16943388](https://pubmed.ncbi.nlm.nih.gov/16943388/).
174. Gomez-Lopez N, Romero R, Plazyo O, Panaitescu B, Furcron AE, Miller D, et al. Intra-Amniotic Administration of HMGB1 Induces Spontaneous Preterm Labor and Birth. *Am J Reprod Immunol.* 2016; 75(1):3–7. Epub 2016/01/20. <https://doi.org/10.1111/aji.12443> PMID: [26781934](https://pubmed.ncbi.nlm.nih.gov/26781934/).
175. Gomez-Lopez N, Romero R, Garcia-Flores V, Leng Y, Miller D, Hassan SS, et al. Inhibition of the NLRP3 inflammasome can prevent sterile intra-amniotic inflammation, preterm labor/birth, and adverse neonatal outcomes. *Biology of reproduction.* 2019; 100(5):1306–18. Epub 2019/01/01. <https://doi.org/10.1093/biolre/boy264> PMID: [30596885](https://pubmed.ncbi.nlm.nih.gov/30596885/).
176. Gotsch F, Romero R, Chaiworapongsa T, Erez O, Vaisbuch E, Espinoza J, et al. Evidence of the involvement of caspase-1 under physiologic and pathologic cellular stress during human pregnancy: a link between the inflammasome and parturition. *J Matern Fetal Neonatal Med.* 2008; 21(9):605–16. Epub 2008/10/02. <https://doi.org/10.1080/14767050802212109> PMID: [18828051](https://pubmed.ncbi.nlm.nih.gov/18828051/).
177. Plazyo O, Romero R, Unkel R, Balancio A, Mial TN, Xu Y, et al. HMGB1 Induces an Inflammatory Response in the Chorioamniotic Membranes That Is Partially Mediated by the Inflammasome. *Biology*

- of reproduction. 2016; 95(6):130. Epub 2016/11/04. <https://doi.org/10.1095/biolreprod.116.144139> PMID: [27806943](https://pubmed.ncbi.nlm.nih.gov/27806943/).
178. Gomez-Lopez N, Romero R, Tarca AL, Miller D, Panaitescu B, Schwenkel G, et al. Gasdermin D: Evidence of pyroptosis in spontaneous preterm labor with sterile intra-amniotic inflammation or intra-amniotic infection. *Am J Reprod Immunol*. 2019; 82(6):e13184. Epub 2019/08/29. <https://doi.org/10.1111/aji.13184> PMID: [31461796](https://pubmed.ncbi.nlm.nih.gov/31461796/).
  179. Gomez-Lopez N, Motomura K, Miller D, Garcia-Flores V, Galaz J, Romero R. Inflammasomes: Their Role in Normal and Complicated Pregnancies. *J Immunol*. 2019; 203(11):2757–69. Epub 2019/11/20. <https://doi.org/10.4049/jimmunol.1900901> PMID: [31740550](https://pubmed.ncbi.nlm.nih.gov/31740550/).
  180. Gervasi MT, Romero R, Bracalente G, Erez O, Dong Z, Hassan SS, et al. Midtrimester amniotic fluid concentrations of interleukin-6 and interferon-gamma-inducible protein-10: evidence for heterogeneity of intra-amniotic inflammation and associations with spontaneous early (<32 weeks) and late (>32 weeks) preterm delivery. *J Perinat Med*. 2012; 40(4):329–43. Epub 2012/07/04. <https://doi.org/10.1515/jpm-2012-0034> PMID: [22752762](https://pubmed.ncbi.nlm.nih.gov/22752762/).
  181. Son GH, You YA, Kwon EJ, Lee KY, Kim YJ. Comparative Analysis of Midtrimester Amniotic Fluid Cytokine Levels to Predict Spontaneous Very Pre-term Birth in Patients with Cervical Insufficiency. *Am J Reprod Immunol*. 2016; 75(2):155–61. Epub 2015/11/22. <https://doi.org/10.1111/aji.12451> PMID: [26589553](https://pubmed.ncbi.nlm.nih.gov/26589553/).
  182. Maritati M, Comar M, Zanotta N, Seraceni S, Trentini A, Corazza F, et al. Influence of vaginal lactoferrin administration on amniotic fluid cytokines and its role against inflammatory complications of pregnancy. *J Inflamm (Lond)*. 2017; 14:5. Epub 2017/03/16. <https://doi.org/10.1186/s12950-017-0152-9> PMID: [28289333](https://pubmed.ncbi.nlm.nih.gov/28289333/).
  183. Fitzgerald W, Freeman ML, Lederman MM, Vasilieva E, Romero R, Margolis L. A System of Cytokines Encapsulated in ExtraCellular Vesicles. *Sci Rep*. 2018; 8(1):8973. Epub 2018/06/14. <https://doi.org/10.1038/s41598-018-27190-x> PMID: [29895824](https://pubmed.ncbi.nlm.nih.gov/29895824/).